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ABSTRACT 
 
 
Cardiovascular disease rarely manifests in pre-menopausal women meanwhile, the incidence of 
these pathologies dramatically increases after the menopause suggesting the possibility that sex 
hormones could have a key role. 17β-estradiol is the main female circulating hormone in the 
premenopausal period and showed protective effects on the cardiovascular system. Moreover, 
recent evidences underlie the importance to take into account the gender in clinical studies as it can 
influence the response to cardiovascular medications. Therefore, we hypothesize that sex hormones 
can also influence the cardioprotective effects of nutraceutical compounds, such as sulforaphane, 
isothiocyanate present in Brassica vegetables. This study was designed to investigate the protective 
effects of sulforaphane in presence of 17β-estradiol against H2O2-induced oxidative damage in 
cardiomyocytes. 17β-estradiol enhanced sulforaphane cardioprotection against H2O2-induced cell 
death with respect to 17β-estradiol or sulforaphane alone, as measured by 3-(4,5-dimethylthiazol-2-
yl)-2,5diphenyl-tetrazolium bromide and lactate dehydrogenase assays. Moreover, 17β-estradiol 
boosted sulforaphane antioxidant activity, reducing intracellular reactive oxygen species and 8-
hydroxy-2′-deoxyguanosine levels and increasing the expression of phase II enzymes. The observed 
effects seem to be not mediated by estrogen receptor α and β, as we used specific antagonists. 
Otherwise, ERK1/2 and Akt signaling pathways seem to be involved, as the treatment with specific 
inhibitors reduced the protective effect of sulforaphane/17β-estradiol co-treatment. Furthermore, 
estrogen receptor β and G protein-coupled receptor 30 seem to contribute to Akt activation, as using 
receptor specific agonists sulforaphane-induced Akt phosphorylation was enhanced. The activation 
of Akt kinase is also involved in the activation of Nrf2 transcription factor elicited by 
sulforaphane/17β-estradiol co-treatment, as treated cells with Akt-inhibitor, the co-treatment-
induced Nrf2 activation was prevented. Our results demonstrated, for the first time, that estrogen 
could enhance sulforaphane protective effects, suggesting that nutraceutical efficacy might be 
modulated by sex hormones. 
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1. CARDIOVASCULAR DISEASE AND SEX-GENDER 
DIFFERENCES 
 
 
Nowadays, cardiovascular disease (CVD) still remain the most common cause of 
death worldwide, with 4 million people dying only across the European continent, 
every year 
1
. Although they have always been perceived as pathologies regarding 
essentially males, it is now clear that a sex-gender component is involved in the 
incidence and death from cardiovascular events. Furthermore, the development of 
coronary artery disease occurs ten year later in women than men 
2
. Indeed, the 
protection from cardiovascular events during fertile period in women dramatically 
decrease after menopause, so that the major cause of death in women after 65 years 
of age is CVD 
3, 4
. Many aspects of CVD are similar in males and females but 
obviously they differ in the anatomy and physiology of the cardiovascular system and 
some differences in risk profile, symptoms, age of onset and response to medical 
treatments have been evidenced 
5
.  
These differences are due in part to the biological differences between men and 
women, usually defined as sex differences, meanwhile the individual interaction with 
the society and environment results in gender differences. These two concepts are 
separated but intertwined in medicine, because they interact and become tangled 
together (Fig. 1.1) 
6
.  
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Figure 1.1: Schematic representation of the interaction between sex and gender 
7
 
 
In fact in this scenario it's also clear that sex hormones can influence behavior and 
lifestyle 
6
. However, studies analyzing the impact of sex and gender in health and 
disease are still inadequate. Despite it has been cleared that there are also sex-gender-
related differences in the pharmacokinetics (i.e. how the drugs are absorbed, 
distributed, biotransformed and excreted) and pharmacodynamics (Fig. 1.2) (i.e. how 
the drug interacts with the site of action), a real clinical relevance of these differences 
is moderate or remains uncertain due to underrepresentation of women in clinical 
trials 
2
.  
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Figure 1.2: Schematic representation of a drug pharmacokinetics and pharmacodinamics 
2
. 
 
So the current guidelines on CVD are based on evidences mostly obtained in middle-
aged men, implying low appropriateness for therapeutic interventions in women 
2
. 
  
 
1.1 Ischemic Heart Disease (IHD) 
 
Ischemic heart disease develops differently in men and women. Men are prone to 
occlusive artery disease linked to a more pronounced and severe atherosclerosis in 
their coronary arteries, which they develop earlier than women, with the consequence 
of precocious myocardial infarction 
7
. On the other side, women experience 
myocardial ischemia, which is due to an imbalance between oxygen supply and the 
demand of the myocardium, for pathological vasoreactivity 
8
. Commonly, perfusion 
problems in women arise from spasm and endothelial dysfunction, or from 
microvascular dysfunction. 
The reason why pre-menopausal women develop less atherosclerosis than men is 
poorly investigated. It has been suggested that it could be related both to a better lipid 
profile than men and to a protective effect mediated by sex hormones. Women with 
hormonal disorders experience atherosclerosis early than healthy women 
7
. 
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Acute mortality after myocardial infarction (MI) is major in younger women than 
age-matched men 
9
. In general, different studies conducted worldwide evidenced that 
women have a higher mortality rate than men for MI, and women die more from 
cardiac rupture at acute MI 
9
. 
Takotsubo syndrome is an IHD manifestation which affects predominantly women, 
and appears as an acute coronary syndrome, though the exact etiopathology is 
unclear. Probably, the lowering in estrogen levels, which occurs in post-menopausal 
period, makes heart more sensible to catecholamines activity 
7
. However, this 
syndrome often manifests in pre-menopausal women after a marked acute 
psychological or physical stress, other cause of increased in catecholamines activity 
on heart. Most of the patients recover a normal ejection capacity, despite the recent 
epidemiological data showed a mortality of 8% per year 
10
. 
 
 
1.2 Hypertension 
 
The prevalence in hypertension related to gender is different if we compare young or 
old population. Whereas there are more young males with hypertension, the situation 
totally capsizes in the old population where the percentage of women with 
hypertension is double than men 
11
. Moreover, at older ages, women are more prone 
to develop vascular and myocardial harshness than men, and frequently they present 
aortic harshness, reflecting a systolic hypertension
12
. Nevertheless,  hypertensive 
women maintain major left ventricular ejection fraction than men 
13
. 
 
 
1.3 Pressure Overload 
 
The adaptation of female heart to pressure overload is different from male. During 
progression of aortic stenosis more often women preserve myocardial contractility 
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and ejection fraction than men, and this could be due to a minor induction of collagen 
remodeling 
14
. In a study from Petrov et al. 
15
 in patients undergoing aortic valve 
replacement, the same percentages of women and men had a superior diameter of left 
ventricle than reference values, but after surgery,  this superiority persisted in major 
percentage in men than in women. Also hypertrophy reversed more in women than in 
men. All these effects are connected to a different collagen I, collagen III and matrix 
metalloproteinase 2 gene expression, so that less fibrosis prior surgery can promote a 
faster regression 
15
. Overall, the studies demonstrated sex-specific pattern in  
myocardial remodeling. 
 
 
1.4 Exercise-induced Cardiac Hypertrophy  
 
Few data have been collected about endurance-induced hypertrophy, and so far a 
different cardiac adaptation was described. Women and men undergoing identical 
training program experience different metabolic adaptation 
16
. In particular, women 
had more body fat reduction in 6 months of training whereas men had a reduction 
only after 12 months. Moreover, women had similar or greater increase in left 
ventricular mass as men after 3 months, but not further increase going on with 
training, instead the greater increase in men left ventricular mass was at month 12. 
Cardiac hypertrophy stimuli in women is controlled by phosphatidylinositol 3-
kinase/Akt and/or β-catenin pathways. In pre-menopausal period women exhibit 
greater Akt cardiac activity with anti-hypertrophic predominant effect 
17
. 
Hypertrophy in men could be partially explained as an effect of testosterone, that is 
known to increase with physical activity 
18
. However more data are needed in this 
context. 
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1.5 Heart Failure 
 
Heart failure (HF) is a chronic, progressive condition in which the heart muscle is 
unable to pump enough blood for the body needs in terms of blood and oxygen. In 
Western societies HF affects more than 10% of people over 70 years, and derives 
from different pathophysiological conditions 
7
. Different forms of HF exist, with 
reduced ejection fraction (typical of men), and with preserved ejection fraction 
(affecting predominantly women) 
19
. Generally, the clinical outcomes for both 
syndromes are better for women, with a different adaptation of the heart with respect 
to men 
20
.  Women develop less ventricular dilatation than men, though they present 
smaller and stiffer ventricles probably due to the different composition in fibrous 
tissue, but maybe also related to different calcium handling which comports variable 
relaxation kinetics 
21
.  
 
 
1.6 17β-estradiol and cardioprotection 
 
Estrogens belong to steroid hormone family which includes also glucocorticoids, 
mineralcorticoids, androgens and progesterone. All steroid hormones derive from 
cholesterol and they share the same key chemical structure (cyclopentane-perhydro-
phenanthrenic) (Fig. 1.3). The synthesis of sex hormones starts early during 
embryonic development. They are mainly synthesized in gonads, but exist also an 
extragonadal synthesis in cardiomyocytes, bone cells and neurons. Sex hormones act 
with many mechanisms, as they belong to the vast family of endogenous signaling 
molecules, which modulate different cellular processes via gene and protein 
regulation. The main female circulating hormone is 17β-estradiol (E2), major product 
of ovary secretion, which owns the strongest potency and has the capability to bind 
all subtypes of estrogen receptors. Other naturally occurring estrogens are estrone (12 
times less potent than E2), produced in both males and females in less extent with 
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respect to E2, meanwhile estriol (80 times less potent than E2) unlike E2 and estrone 
is not synthesized in or secreted from the ovaries but it mainly derives from 16α-
hydroxylation of the other two estrogens, by cytochrome P450 enzymes in liver. 
 
 
 
Figure 1.3: Biosynthesis of sex hormones 
22
. 
 
As mentioned before, E2 can also be produced locally as a result of the conversion of 
testosterone by the enzyme aromatase 
23
. Aromatase is present in a number of 
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extragonadal tissues, such as the adipose tissue, bone, brain, heart, and the 
vasculature in both sexes 
24
. 
It has been proposed that E2 possesses cardioprotective activity and acts through 
different mechanisms. E2 reduces cardiomyocyte apoptosis in vivo and in vitro 
through estrogen receptors (ERs) and phosphoinositide-3-kinase (PI3K)/Akt 
signaling pathways 
25, 26. E2 differentially modulates p38α and β MAPK during 
hypoxic/oxidative stress, preventing apoptosis and counteracting mitochondrial 
reactive oxygen species (ROS) generation in cardiomyocytes 
27
. In cardiomyocytes, 
E2 is also able to differently modulate prohypertrophic (class I) and antihypertrophic 
(class II) histone deacetylase proteins through the binding to ERβ, thus counteracting 
cardiac hypertrophy 
28
. It has also been shown that SIRT1 (class III) functions as an 
important regulator of E2-mediated cardiomyocyte protection during angiotensin-II-
induced heart hypertrophy and injury 
29
. 
In vascular smooth muscle cells, E2 possesses antioxidant activity 
30
 and up-regulates 
the expression of genes as endothelial nitric oxide synthase (eNOS), superoxide 
dismutase (SOD), and down-regulates NADPH oxidase in the cytoplasm 
31
, thus 
contributing to its vasoprotective effects. 
Moreover, in cardiomyocytes, E2 exposure up-regulates corticotrophin-releasing 
hormone receptor type 2 expression by interacting with ERα and enhances the 
protective effect of urocortin against hypoxia/reoxygenation 
32
. In the H9C2 
myocardial cell line, Hsieh et al. 
33
 showed that E2 provides cardioprotection through 
the inhibition of hypoxia induced HIF-1α and downstream BNIP3 and IGFBP3-
dependent apoptotic responses. Furthermore, E2 cardioprotective effects were also 
confirmed in animal models: E2 prevented Fas-dependent and mitochondria-
dependent apoptotic pathways, and cardiac hypertrophy induced by ovariectomy, in 
rat models 
34, 35
; E2 reduced infarct size and exerted a protective effect on ischemic 
myocardium in rabbits, mice, and rats 
36-38
; E2 prevented global myocardial 
ischemia/reperfusion injury in rats 
39
. The specificity of these effects was well 
documented by the reversion of the effect using ER antagonist ICI182780 
40, 41
. The 
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administration of E2 was also demonstrated to exert antihypertrophic effects in 
various models of pressure overload. The mechanisms involved are: the inhibition of 
the expression of prohypertrophic genes and the reduction of left-ventricular 
hypertrophy 
42
; the regulation of two proteins involved in the hypertrophy 
development, such as atrial natriuretic factor and myosin heavy chain beta 
43, 44
; the 
reduction of systolic dysfunction and fibrosis with the involvement of ERα in 9-
weeks administration model 
45
. 
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2. ESTROGEN RECEPTORS AND SEX-GENDER 
DIFFERENCES IN CARDIOVASCULAR SYSTEM 
 
 
Before 1996, only one estrogen receptor has been discovered and the predominant 
idea was that all estrogen effects were mediated by this receptor that acted as a 
ligand-regulated transcription factor. Now we refer to this receptor as ERα. Over the 
past 20 years the knowledge about estrogen signaling has grown, so that now three 
different receptors have been characterized: ERα, ERβ and G protein-coupled 
receptor 30 (GPR30), which can act through traditional transcription regulation as 
well as by non-genomic pathways. 
 
 
2.1 Chemical structure and localization of Estrogen receptors 
 
ERα and ERβ belong to the superfamily of nuclear steroid hormone receptors. Like 
all steroid receptors they have: an amino (NH2)-terminal region, A/B domain, which 
contains constitutive AF-1 (activation function 1) that acts on target gene 
transcription in a ligand-independent way; a zinc finger-based DNA-binding domain 
(DBD) named as C region, which contains regions that mediate dimerization; a hinge 
domain (D region) which connects C region to E region and it is the binding site for 
heat shock protein 90; a carboxy (COOH)-terminal ligand-binding domain (LBD) (E 
region), which contains the ligand-dependent activation function (AF-2) 
7
 (Fig. 2.1). 
They have been identified in several cardiovascular cells from male and female 
individuals, such as cardiomyocytes, cardiac fibroblasts, vascular smooth muscle 
cells and vascular endothelium 
46-49
. 
Interestingly in human heart, ERα mRNA levels are similar in men and women, 
meanwhile ERβ mRNA levels are more abundant in men than in women 50. 
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A part of the classical localizations at the plasma membrane and nucleus, both ERs 
have also been detected in mitochondria 
51
. 
 
 
 
Figure 2.1. Domain organization and sequence homology of human ERα and ERβ 52. 
 
 
Only in the last decade, GPR30 emerged as an important mediator of non-genomic 
estrogen actions. It is a G-protein coupled receptor, so belongs to the largest known 
class of membrane receptors (Fig. 2.2). The most important characteristic of G-
protein coupled receptors is the presence of seven transmembrane alpha helices, and 
as the name implies they interact with G-proteins. G-proteins are specialized proteins 
with the ability to bind guanosine diphosphate (GDP) and guanosine triphosphate 
(GTP), and all those that associate with G-protein coupled receptors are 
heterotrimeric, meaning they have three different subunits (α-, β-, and γ-subunit). 
GPR30 protein is structurally different from classical ERs but it possesses the same 
binding characteristics 
53
.  
The expression of GPR30 has been identified in multiple tissues, such as ovary, 
uterine endometrium, brain, kidney, adrenal, breast, heart and endothelium 
54-56
. 
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Instead, regarding GPR30 cellular location there is some debate, because some 
research groups found it localized in the endoplasmic reticulum and the Golgi 
apparatus but not in plasma membrane 
57
, meanwhile other reported GPR30 to 
localize in plasma membrane 
58, 59
. Cheng et al. 
60
, showed a constitutive endocytosis 
for GPR30, which results in a half-life of 30 minutes, demonstrating its presence also 
in endosomes and endoplasmic reticulum. 
 
 
Figure 2.2. Structure of GPR30 (modified from 
61
). 
 
 
 The GPR30 rapid recycle from plasma membrane through endosomes formation 
could explain why data on receptor localization are not clear. Therefore, the 
localization of GPR30 appears to be heterogeneous, but so far data for functionality 
at endoplasmic reticulum level are uncertain. 
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2.2 Estrogen genomic effects 
 
E2 activating ERs can regulate gene expression through different pathways: 1) direct 
binding to DNA; 2) indirect binding to DNA through other transcription factors; 3) 
ligand-indipendent binding 
62
 (Fig. 2.3). 
In the classical mechanism, E2 binds ER facilitating its dissociation from cytoplasmic 
chaperones and promoting its translocation to the nucleus and its dimerization, thus 
facilitating the binding to ERE sequence (estrogen response element) in the DNA and 
mediating the regulation of gene expression. In this case coactivators and 
corepressors can activate or inhibit gene expression. E2 can also regulate gene 
expression via the mediation of ER-tethering with transcription factors, such as 
activator protein-1 and specificity protein-1, so acting via non-ERE pathways 
63
; 
alternatively, growth factors and E2 can activate kinase signaling pathways leading to 
the phosphorylation of a specific serine site on ERs 
64
, significant for the induction of 
the trascription via ligand-indipendent or ERE-pathway. 
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Figure 2.3. Genomic ER signaling 
62
.  
 
 
2.2.1 Distinct roles for ERα and ERβ genomic effects, who wins? 
 
The analysis of ERs genomic effects is really difficult for several reasons. First of all, 
there are variations in ERα and ERβ protein levels that are temporal and tissue-
related, moreover their levels and also coactivators and corepressors levels can vary 
during ageing, diseases, and with sex, so modifying E2 effects. 
In wild type mice aorta O'Lone et al. 
65
, examining aorta whole vessels after long-
term exposure to E2, showed that ERα was sufficient and necessary for the induction 
of some genes, meanwhile for another group of genes both receptors ERα and ERβ 
act in concert to stimulate gene expression. The same study revealed the involvement 
of ERβ in down-regulating some genes, including several nuclear-encoded 
~ 15 ~ 
 
mitochondrial genes, supporting its role in a gene active repression and not simply an 
opposite effect to ERα. 
Nikolic et al. examined the effects of 2 h heart perfusion with a selective ERβ 
agonist, revealing a cardioprotective effect mediated by the up-regulation of different 
genes. These different results could be due to the diverse exposition times and cells 
(aorta or ventricular myocytes) 
66
.  
Studies explored the roles of both ERs after myocardial infarction, using unique 
models of cardiac-specific ER overexpression (OE) in mice. ERα-OE protects the 
heart from ischemic damage, enhancing neovascularization of peri-infarct area and 
inducing less fibrotic genes 
67. ERβ-OE mice showed improved survival after 
myocardial infarction, likely for a better sustenance of Ca
2+ 
cycling and attenuated 
cardiac fibrosis 
68
. 
Also in vitro models have been explored for ERs differential genomic regulation. 
Endothelial nitric oxide synthase (NOS), the enzyme primarily responsible for the 
generation of nitric oxide (NO) in the vascular endothelium 
69
, was up-regulated by 
ERα in endothelial cells 70, whereas ERβ was responsible for the induction in cardiac 
muscle 
71
.  
As mentioned also before, both ERs can act in concert to regulate gene expression. In 
endothelial cells, they contrast the over-generation of reactive oxygen species (ROS) 
from mitochondria, up-regulating superoxide dismutase 2 (SOD2), with the result of 
a lower mitochondrial dysfunction and vascular damage 
72
.  
 
 
2.3 Estrogen non-genomic signaling 
 
The first report of a non-genomic response by estrogen has been showed in the 1960s 
by Pietras and Szego 
73
. They demonstrated a rapid response on cAMP concentration 
in endometrial cells, within minutes from E2 exposure.  
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It is now well characterized that physiological concentrations of E2 can induce 
cellular rapid responses, which do not involve protein synthesis or gene transcription, 
and that are controlled by receptors localized on plasma membrane 
74, 75
 (Fig. 2.4). 
 
 
 
 
Figure 2.4. Non genomic ER signaling 
62
. 
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2.3.1 ERα and ERβ signaling 
 
ERs localize at plasma membrane for a ≈ 5%-10% of their total amount 76. 
Unfortunately, the distribution of membrane-bound ERs in the cardiovascular tissues 
is poorly investigated, but both ERα and ERβ have been found in vascular endothelial 
cells 
77. In the other tissues, the relative distribution of ERα and ERβ at the plasma 
membrane is different among cell type; in breast cancer cells ERβ is more abundant 
than ERα 78, and the opposite is true for the reproductive cells 79. 
Post-translational modifications are found to be involved in the binding of ERs to 
plasma membrane, such as palmitoylation that increases the association of the 
receptors to plasma membrane 
80, 81
. 
Moreover, several studies identified different sites on ERα, important for its 
localization to the plasma membrane. Ser522 is required for the interaction between 
ERα and caveolin-1, facilitating the receptor  binding to caveolae 80, 82, but the 
mutation of this residue does not block the traslocation of ERα to the membrane as 
reported by Razandi et al., suggesting that Ser522 is not the only residue involved in 
the membrane association 
82
. Palmitoylation of Cys447 has been reported to be 
crucial for membrane localization of ERα 82, 83. Therefore, the group of Levin 
identified in human and mouse cells an amino acid motif in estrogen binding domain 
of both ERα and ERβ, as involved in the membrane traslocation, and Cys447 residue 
is part of this motif 
84
. 
The palmitoylation can happen only on ER monomer, so if dimerization occurs, such 
as after estrogen binding, the receptors available for palmitoylation are less and in 
turn less receptors translocate to the membrane 
62
. Another mechanism involved in 
the trafficking to plasma membrane is the binding between heat shock protein 27 and 
palmitoylation site on ERα monomer 82. 
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2.3.1.1 Cardiomyocytes 
 
Unfortunately, only few studies have been conducted to examine the role of ERs non-
genomic pathways in cardiomyocytes.  
Short-term treatment with E2 is able to improve heart function after I/R injury, and 
this effect is reversed in the presence of NOS inhibitor,  suggesting the contribution 
of NO production via ER activation in this process 
85
. Other studies demonstrated that 
non-genomic estrogen signaling by ERβ can act on cardiac hypertrophy 43, 86. 
Moreover, the involvement of this receptor has been elucidated by another study, 
which found that the prevention on angiotensin-induced hypertrophy elicited by E2 
was abolished in ERβ knockout mice 87. The effects on cardiomyocyte hypertrophy 
were due to sequestering of transcription factors in the cytoplasm which prevents 
target gene activation. 
 
 
2.3.1.2 Endothelial cells 
 
E2 can stimulate eNOS phosphorylation in endothelial cells (EC) activating 
membrane-localized ERs 
88
. Endothelial eNOS activation is a main pathway in the 
regulation of vascular relaxation, EC proliferation and migration. Endothelium health 
is really important in the cardiovascular system, indeed endothelial dysfunction is 
responsible for an increased cardiovascular risk 
89
. E2 is able to activate eNOS by 
several signaling pathways. After E2 binding at membrane level, ERα forms a 
complex with the regulatory subunit of PI3K, p85α, and with c-Src at the SH2 
domain 
90
. This complex leads to the activation of protein kinase B (Akt), 
extracellular-signal-regulated kinases 1/2 (ERK1/2) and also phosphorylation and 
activation of eNOS 
91
. In agreement, the pre-treatment with E2 in mice exposed to I/R 
injury, increased eNOS activation and decreased leukocyte accumulation at vascular 
level, and the protective effect was abolished using PI3K or eNOS inhibitors 
74
.  
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Moreover, ERα can interact with G proteins Gαi and Gβγ, leading to eNOS activation 
and stimulation of cell migration 
92
. 
In addition to the effects on eNOS, physiological concentrations of E2 (10
-9 
mol/L) 
can modulate intracellular calcium homeostasis through non-genomic pathways. E2 
was able to cause a rapid increase in intracellular calcium levels in both human and 
rat EC, and in this last cell type, the effect was blocked using the ER antagonist ICI 
182,780 
93, 94
.  
 
 
2.3.1.3 Vascular Smooth Muscle Cells 
 
It has been reported that E2 can rapidly inhibit vascular smooth muscle cells 
(VSMCs) proliferation 
95, 96
. The proliferation of VSMCs is implicated in 
cardiovascular disease, particularly in atherosclerosis 
62. The activation of ERα 
through E2 treatment induces the activity and the expression of different 
phosphatases, such as protein phosphatase 2A, MAP kinase phosphatase-1 and so on. 
Therefore, stimulating these phosphatases which lead to the dephosphorylation of 
kinases, E2 induces a stop in cell migration and growth 
95, 97, 98
. Karas et al. 
99
 
evidenced the role of E2 on blocking VSMCs proliferation, thanks to an enhanced 
activity of phosphatase 2A on phosphorylated Akt. This outcome was controlled by 
the complex formed between ERα and phosphatase 2A. In the same study, the 
researchers evidenced that in cells derived from a transgenic mouse line, which 
overexpressed a peptide that disturb the trafficking of ERs to plasma membrane, E2 
did not influence cell proliferation. Data from microarray analysis confirm that 
disturbing ERs non-genomic signaling alters transcriptional response to E2 treatment. 
The genes involved are those associated with vascular function, so underling the 
importance of short term signaling on vascular health 
100
. 
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2.3.2 GPR30 signaling 
 
The expression of GPR30 is ubiquitous, so it is not surprising that its activation has 
been connected to multiple biological activities, such as production and secretion of 
IL-10 in immune system 
101
; cardiovascular and cancer cell growth and death 
102, 103
; 
effects on depression disorders 
104
. 
The signaling cascade initiated by GPR30 involves the activation of a stimulatory G 
protein and the subsequently formation of cAMP after activation of adenyl cyclase. 
Interestingly, E2 is able to trigger this rapid intracellular response, whereas estrone 
and estriol are inactive. Moreover, many other signaling pathways have been linked 
to GPR30 activation, as epidermal growth factor receptor (EGFR) 
105
, PI3K 
106
, and 
ERK pathways 
107
. 
 Of note, these pathways are the same widely studied as non-genomic pathways 
mediated by ERα and ERβ 91. 
 
 
2.3.2.1 Vascular effects 
 
Several reports aimed to investigate the vascular effects mediated by GPR30.  
Surprisingly the largely used ERs antagonist ICI 182,780 did not attenuate the 
estrogen-induced vasodilatation in arteries 
108, 109
, and the genomic deletion of ERα 
and ERβ did not reverse the cardiac responses mediated by E2 110. Indeed, although 
ICI 182,780 is a well known ERα and ERβ antagonist, it acts as an agonist for 
GPR30. So these discoveries suggest that GPR30 might regulate the vasodilatatory 
effect of E2. To deepen this aspect multiple studies were conducted using the 
selective GPR30 agonist G-1, so confirming the vasodilatative effect of GPR30 in 
both human and non-human arteries, and in vitro, in vivo models 
111-113
. In particular, 
in in vivo models, researchers evidenced a reduction of blood pressure also in 
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normotensive rats with no response in animals knockout for GPR30 
113
, and the total 
vasorelaxation effect after G-1 treatment was about 30% to 40% 
114
.  
 
 
Figure 2.5. GPR30 effect on vasculature via endothelium-dependent and endothelium-independent 
mechanisms 
62
. 
 
 
The GPR30 effects on vasculature involved mechanisms endothelium-dependent and 
endothelium-independent (Fig. 2.5). It has been demonstrated that E2-mediated 
GPR30 activation leads to an increase in NO production 
108
, so supposing its 
implication. But several studies also demonstrated a residual effect in endothelium-
prived vessels after G-1 treatment 
112, 115
. G-1-induced relaxation in coronary smooth 
muscle is supposed to be mediated by a large conductance calcium-activated 
potassium channel. Indeed, it has been evidenced an inhibition in G1-induced 
vasorelaxation, only with the channel block and not when NOS production was 
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inhibited
115
. Vascular remodeling can occur as response to acute or chronic (vascular 
injury, and atherosclerosis) stress factors and includes adaptive and maladaptive 
responses (hypertension and vascular stenosis) 
116
. It is well-known that E2 is able to 
decrease proliferation of VSMC after injury 
62
. Different findings support the role of 
GPR30 in inhibiting the inflammatory response associated with atherosclerosis 
117
 
and proliferation 
118
, meanwhile it stimulates apoptosis 
119
, and mitigates the 
expression of adhesion molecule mediated by TNF 
120
. G-1 agonist also demonstrated 
to be able to reduce DNA synthesis and proliferation in different models of 
endothelial cells interfering with the cell cycle 
121
.  
A role of GPR30 in atheroprotection has also been evidenced. The deletion of GPR30 
gene led to increase in blood pressure, low-density lipoprotein (LDL) cholesterol 
levels, and the presence of inflammation markers 
117
.  
The mechanisms insight this protection are related to cholesterol metabolism. Indeed 
GPR30 activation has been linked to the up-regulation of LDL receptors at hepatic 
level, increasing the clearance of circulating LDL cholesterol; and on the other hand 
GPR30 activation reduces LDL receptor degradation, through the inhibition of 
proprotein convertase subtilisin/kexin type-9 (PCSK9), which is the major 
mechanism for the receptor degradation 
122
.  
 
 
2.3.2.2 Cardiac effects 
 
E2 modulation of cardiac calcium intracellular levels was reported to be ERα and 
ERβ-independent. As confirmation to this, researchers used  cells derived from ERα 
and ERβ knockout mice, and the E2-mediated calcium levels alterations were not 
changed 
110
. The development of a GPR30 knockout model confirmed the role of this 
receptor in the modulation of calcium influx 
113
. Using G-1 agonist a protective effect 
against I/R injury in rat hearts was also evidenced, preserving cardiac contractility, 
reducing infarct size, and the levels of inflammatory markers (TNF, IL-1β, IL-6), and 
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also inhibiting the opening of mitochondria permeability transition pore after the 
injury, so saving cardiac cells from the death 
103, 123-125
. The molecular pathway 
involved in cardiac protection seems to be PI3K signaling, because using a PI3K 
inhibitor reverses G-1 protective effects 
103
. 
 
 
2.3.3 Sex-gender differences 
 
More and more studies aimed to investigate the role of ERs and GPR30 in different 
pathological conditions and consequently to observe the presence of sex-differences. 
For this purpose animal models with specific genetic deletion of these receptors have 
been used.  
The genetic deletion of ERβ (BERKO) in conditions of pressure overload evidenced 
a detrimental consequence for both males and females but for different mechanisms 
126. The presence of ERβ in females reduced fibrosis, cardiomyocytes hypertrophy 
and cell apoptosis, meanwhile in males it promotes fibrosis but again limits 
cardiomyocytes hypertrophy and cell apoptosis 
126
. 
The greater importance of ERβ in females was also confirmed in an I/R model, where 
BERKO females showed a greater degree of injury 
127
. Similarly, in another study E2 
treatment resulted in a smaller infarct size in a model of genetic deletion for ERα 
(ERKO) in respect to BERKO 
128
.  
In a model of exercise-induced hypertrophy ERβ had a role as modulator for sex-
differences 
129
. The cardiac response to exercise in females is modulated by the 
regulation of PKB and MAPK signaling pathways, such as protein synthesis and 
mitochondrial adaptation via ERβ 129. Moreover, the alteration in circulating free fatty 
acids with an augmented adipose tissue lipolysis has been reported. Therefore, sex 
differences in exercise-induced hypertrophy are also related to changes in cardiac 
metabolism, shifting to a greater use of fatty acids in females
130
. 
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Only female BERKO mice with a condition of chronic MI showed a prolonged 
ventricular repolarization with a reduction in automaticity  
131
.  
All these considerations promote the hypothesis of a role for ERβ in mediating a 
mitigated response to several cardiac injuries in females. 
Interestingly, from other studies emerged the role of  ERα in mediating E2-
protection. For example, in I/R injury ERα functionality at endothelial level seems to 
have an important role in the E2-induced prevention of endothelial dysfunction 
132
. 
Studies utilizing ERKO animals evidenced worse cardiac damages after I/R injury in 
the group with the deletion 
133
. 
On the other side, also GPR30 cardiovascular effects could be influenced by sex and 
gender. In particular, regarding vasodilatative effects, the genetic deletion of GPR30 
in a mouse model, comported the increase in blood pressure in females 
134
. Moreover, 
the endothelial-dependent GPR30 effects were also observed to be gender-influenced, 
because in the presence of a NOS inhibitor vasodilatation was reversed only in 
vessels from pregnant women, and partially in those from postmenopausal women, 
meanwhile no effects were demonstrated on vessels from men 
135
.  
The importance of GPR30 in the regulation of blood pressure was also pointed out 
thanks to the identification of a common hypofunctional missense variant of GPR30 
namely P16L 
136, 137
. Individuals carrying the hypofunctional variant showed higher 
blood pressure, as observed in a population of normotensive, especially in 
premenopausal women 
136
. Furthermore, the probability to carry this genetic variant 
was twice in women (mainly postmenopausal) with resistant hypertension 
136
. 
As mentioned in previous paragraph, the deletion of GPR30 gene leads to increase in 
blood pressure, low-density lipoprotein (LDL) cholesterol levels, and the presence of 
inflammation markers 
117
. All these consequences were more pronounced in females 
than in males 
117
. And in two different cohort populations, women but not men, which 
present the hypofunctional receptor variant, showed significantly higher LDL and 
total circulating cholesterol levels 
122
.  
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In conclusion, the results provided from the literature suggest that both ERs are 
important and participate to the cardioprotection by E2. 
Moreover, all observations lead to support the role of GPR30 activation especially in 
the regulation of blood pressure and atherosclerotic risk factors.   
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3. OXIDATIVE STRESS AND CARDIOVASCULAR DISEASE 
 
 
3.1 Oxidative stress 
 
Oxidative stress is a condition of disequilibrium between oxidative species, mainly 
reactive oxygen species (ROS), and the endogenous antioxidant defenses (Fig 3.1). 
This condition refers to overall alterations that can occur at tissue, cellular and 
biological macromolecule level. ROS and other reactive species are a natural by-
product of different biochemical processes and adequate quantities are essential for 
the homeostasis maintenance and for cell signaling. In this regard, the 'redox window' 
hypothesis has been postulated: adequate ROS production is needed for physiological 
cellular functions, but an excess of ROS levels can contribute to the development of 
pathological conditions 
138
. The alteration of the normal redox state can have 
damaging effects, with the consequence of damage to proteins, lipids and nucleic 
acids leading to different pathological states such as atherosclerosis, CVD, aging, 
diabetes and cancer. 
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Figure 3.1. The balance between antioxidants and oxidants determines oxidative stress [modified from 
139
]. 
 
 
3.2 Free radicals and ROS 
 
Free radical is a chemical specie having one or more unpaired electrons on one 
atomic or molecular orbital. The free radicals are characterized by an extremely high 
reactivity and instability, as they tend to catch the electron they miss from other 
molecules. They trigger chain reactions leading to shutdown of starting radical and/or 
to the generation of a new radical. The free radicals most involved in cellular 
processes are the ROS 
140, 141
. Sources of ROS production are many and include 
NADPH oxidase, uncoupled nitric oxide synthases, xanthine oxidase and 
mitochondria 
142
 (Fig 3.2). 
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Figure 3.2. Representation of the main ROS  sources [modified from 
143
]. 
 
 
Our body produces different kinds of ROS, such as superoxide (O2
•-
) and hydroxyl 
(OH
•
) free radicals, and hydrogen peroxide (H2O2) which is a non-free radical.  
H2O2 is relatively stable but with strong oxidative properties 
144
 and its production can 
be mediated by superoxide dismutation and peroxidase enzymatic reactions  in 
peroxisomes 
145
. It represents the main ROS involved in cellular signaling, as it acts 
activating several cellular signaling pathways as secondary messenger 
146
. This is due 
to its longer half-life in respect to other free radicals and ability to permeate through 
cellular membranes 
147
. 
The production of H2O2 is particularly increased in inflammatory conditions 
146, 148
. In 
addition to the oxidative stress condition which comports alteration of cellular 
functionality, apoptosis or necrosis, ROS can also cause post-translational 
 
 
Figure 3.2.  
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modifications involving important cellular proteins and signaling pathways in the 
heart 
149-151
. 
 
 
3.3 Enzymes involved in ROS production 
3.3.1 NADPH oxidase 
 
NAD(P)H oxidase (Nox) is an enzyme catalyzing O2
•- 
or H2O2 release by reduction of 
molecular oxygen using as electron donor NAD(P)H, in various intracellular and 
extracellular compartments 
152
. Several isoforms of Nox were described in various 
cardiovascular cells such as enodthelial cells and VSMC. In particular Nox1 and 
Nox2 isoforms represent an important source of ROS at vascular level in different 
pathological conditions, as hypertension, diabetes and atherosclerosis 
152
. However 
generation of ROS through Nox enzymes have also a physiological role in various 
processes, including immune system reactivity and redox-dependent signaling 
pathways. The activation of Nox enzyme needs of  the assembly of multiple protein 
components in the cell membrane 
153
 (Fig. 3.3).  
 
 
Figure 3.3. Schematic representation of NADPH oxidase activation [modified from 
153
]  
 
 
 
 
Cell 
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3.3.2 Xanthine oxidase 
 
Xanthine oxido-reductase system is involved in purine catabolism, it oxidizes 
hypoxanthine to xanthine, and then xanthine to uric acid 
154
. The system consists of 
two interconvertible forms, the liver synthesizes xanthine dehydrogenase that under 
pathophysiological conditions, such as ischemia and reperfusion, undergoes 
proteolysis releasing xanthine oxidase (XO) 
154
. XO can associate with 
glycosaminoglycans present in endothelial cells and localizes with them 
155
. As for 
Nox enzymes, XO catalyzes the reduction of molecular oxygen to superoxide and 
hydrogen peroxide. Circulating levels of XO were increased in animal models of 
hypercholesterolemia and using a XO inhibitor as oxypurinol the superoxide levels 
were reduced leading to an improved endothelial function 
155, 156
.   
 
 
3.3.3 Mitochondrial respiratory chain enzymes 
 
Complex I and III are responsible for the production of a substantial amount of 
superoxide in mitochondrial electron transport chain. Superoxide is released into the 
mitochondrial matrix by complex I so reversing the electron flow from complex II. 
Complex III releases superoxide into the mitochondrial intermembrane space. 
Mitochondria are cellular organelles really sensitive to oxidative damage. Increased 
ROS production slows their activity and promotes further ROS release 
157
. Moreover, 
mito-ROS can subsequently activate other ROS sources 
158
. Increased mito-ROS 
levels can lead to the release of apoptotic agents 
159
. 
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3.3.4 Endothelial nitric oxide synthase (eNOS) 
 
eNOS enzyme has a key function in the endothelium for its production of NO which 
induces vasodilatation, prevents atherogenesis and inhibits platelet aggregation and 
adhesion 
160
. Similarly to the other NOS isoforms, eNOS switches electrons from 
NADPH, via the flavins flavin adenine dinucleotide and flavin mononucleotide in the 
carboxy-terminal reductase domain, to the heme in the amino-terminal oxygenase 
domain. Here, the substrate L-arginine is oxidized to L-citrulline and NO 
160
 (Fig. 
3.4). Inadequate amount of NO production can lead to endothelial dysfunction. 
Oxidative stress is markedly implicated in endothelial dysfuction, because the excess 
of superoxide rapidly inactives NO forming peroxynitrite (ONOO
-
). The essential 
NOS cofactor (6R-)5,6,7,8-tetrahydrobiopterin (BH4) is highly sensitive to oxidation 
by ONOO(-) 
161
. All this lead to eNOS impairment and it is no longer able to produce 
NO but rather it become a source of superoxide 
160
. eNOS uncoupled has been found 
in various animal models and in patients with endothelial dysfunction 
160
.  
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Figure 3.4. Schematic representation of eNOS-mediated NO synthesis 
162
. 
 
 
3.4 Antioxidant defenses 
 
As mentioned before ROS are extremely reactive and can induce damages in all 
cellular districts. They are able to modify and inactivate proteins and oxidize 
membrane phospholipids (lipid peroxidation) altering the composition of plasma 
membrane. In particular, H2O2 which is able to cross the membrane, can interact with 
the DNA inducing mutations. In addition, it has been demonstrated the direct 
correlation between oxidative stress and inflammation, as ROS can activate NF-kB, a 
key factor for inflammation 
163
. NF-kB is a transcription factor which regulates the 
expression of many proteins involved in inflammatory processes (cytokines, adhesion 
molecules, inflammatory enzymes and several receptors) 
164
. 
Our organism is able to protect cells from the overproduction of ROS by different 
antioxidant defense mechanisms. The defense systems could be: enzymatic and non-
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enzymatic, in the first case, the radical removal happens with a catalytic mechanism, 
while the non-enzymatic defenses have heterogeneous working mechanisms, they can 
bound and sequestrate pro-oxidant molecules, or they can act as radical scavenger; 
intracellular and extracellular depending on whether the site of their action is in or 
out of the cell. The defense systems can be classified as follows: 
 
 enzymatic antioxidants like SOD, CAT, GPx, GR, GST, NQO1, HO-1 and TRXr; 
 intracellular non-enzymatic antioxidants: coenzyme Q and Glutathione (GSH); 
 extracellular non-enzymatic antioxidants:  
o metal chelating agents: albumin, uric acid, metallothionein, ceruloplasmin, 
transferrin; 
o non-enzymatic scavengers: ascorbic acid, tocopherol, carotenoid, and 
polyphenols.  
 
 
3.4.1 Superoxide dismutase (SOD) 
 
SOD is an enzyme belonging to the oxidoreductase class and catalyzes the reaction 
where superoxide is converted to H2O2 
165
: 
 
2 O2
•-
 + 2 H
+
 
 →  H2O2 + O2 
 
For its catalytic activity SOD exploits metallic ions, mainly manganese (Mn), copper 
(Cu) and zinc (Zn). Several isoforms of this enzyme exist which are distinguishable 
for their localization and cofactor (metallic ion). SOD1 localized in the cytoplasm 
and is known as  Cu/Zn SOD, mitochondrial SOD2 is known as MnSOD and SOD3 
is the extracellular form 
165
. 
 
SOD 
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3.4.2 Catalase (CAT) 
 
CAT catalyzes the reduction of H2O2 to H2O and O2 with the follow reaction 
166
: 
 
2H2O2  
 →  2H2O + O2 
 
 
CAT is localized in peroxisomes, citoplasm, and mitochondria.  Its activity is reduced 
when low levels of H2O2 are present meanwhile it tends to increase with increasing 
H2O2 levels 
167
. Cytosolic or mitochondrial CAT overexpression showed protective 
effects against oxidative injury 
168
. 
 
 
3.2.3 Glutathione Peroxidase (GPx), Glutathione Reductase (GR) and Glutathione-S-
transferase (GST) 
 
GPx is together with CAT a key enzyme for H2O2 detoxification. It is a selenium-
dependent enzyme and uses GSH as electron donor for H2O2  or hydroperoxides 
reduction 
167, 169
. During the reaction GSH is oxidized (GSSG)  with the formation of 
a disulfur bridge between two molecules of GSH : 
 
 
H2O2 + 2GSH  →  2H2O + GSSG 
 
2GSH + LOOH  →  GSSG +LOH + H2O 
 
 
 
 
CAT 
GPx 
GPx 
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GSSG can be reduced by GR with a mechanism NAPH-dependent that led to the 
reduction of GSSG to GSH and to the oxidation of NADPH to NADP
+
: 
 
 
GSSG + NADPH  →  2GSH + NADP+ 
 
 
GSTs are a class of enzymes which catalyzes the conjugation of GSH to electrophilic 
compounds : 
 
 
GSH + Xenobiotic  →  GSX + 
 
 
The conjugation with GSH is also the first step of the mercapturic acid pathway, 
maybe the main detoxification process. Several cytosolic isoforms of GST have been 
described and grouped in four classes on the basis of their substrate specificity and 
amino acid sequences: α, µ, π, τ.  
 
 
3.4.4 GSH 
 
GSH is the most abundant cellular non-enzymatic antioxidant. It is a tripeptide, 
synthesized at hepatic level, consisting of glutammic acid, L-lysine and L-glycine, 
and represents the main cellular thiol. GSH synthesis starts from the formation of a γ-
dipeptide by γ-glutamilcystein synthetase, after this the dipeptide bounds glycin by γ-
glutathione synthetase 
170
. 
GR 
GST 
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At cellular level, glutathione can be reduced (GSH) or oxidized (GSSG), contributing 
to the maintenance of optimal redox state. 
GSH is particularly concentrated in organs which are more exposed to toxics, as liver 
and kidney.  
GSH, GPx and GR represent a key system for ROS detoxification thanks to continue 
re-cycling of GSH 
166, 171
. 
 
 
3.4.5 Thioredoxin Reductase (TRXr), NAD(P)H-quinone oxidoreductase (NQO1), 
Heme Oxigenase 1 (HO-1) 
 
Thioredoxin/Thioredoxin Reductase constitutes another important system for H2O2 
detoxification. In particular TRXr acts using NADH to restore the oxidized 
thioredoxin in the reduced form. The reduced form of thioredoxin is needed for the 
reduction of H2O2 to H2O by thioredoxin peroxidase 
172
. 
 
NQO1 is a flavoprotein that catalyzes the reduction of quinone or other similar 
xenobiotics in a two steps reaction with the involvement of two electrons. The 
enzyme uses as cofactor NADH or NADPH indistinctly. The reaction mechanism has 
been named as 'ping pong'. In particular, NQO1 reduces quinone to hydroquinone in 
a two step reaction with the transfer of two electrons, so avoiding the formation of a 
reactive intermediary semiquinone 
173
, which could reacts with O2 leading to ROS 
formation 
174
. 
 
HO system consists of different isoforms and HO-1 is the inducible form in oxidative 
stress condition 
144
. These enzyme family has a key role in the heme catabolism. The 
enzyme cleaves heme ring and converts it to biliverdin using NADH or NADPH. The 
biliverdin is then converted into bilirubin by biliverdin reductase. Moreover bilirubin, 
the final product of heme catabolism showed antioxidant capacities.  
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3.4.6 Modulation of the endogenous defense system by Nrf2/ARE pathway 
 
The nuclear factor (erythroid-derived 2)-related factor 2 (Nrf2)/ antioxidant 
responsive element (ARE) pathway is the main regulator of cytoprotective responses 
to oxidative and electrophilic stress 
175, 176
. Nrf2, under basal condition, has a short 
half life within 7-15 minutes because it is rapidly degradated 
177, 178
. 
In normal (basal) conditions Nrf2/ARE pathway is repressed by the sequestration of 
Nrf2 in the cytoplasm where it is continuously degradated. In cytoplasm Nrf2 binds 
the cysteine-rich Kelch-like ECH associated protein 1 (Keap1), which represents its 
major negative regulator and that forms a RING E3-ubiquitin ligase with Cullin 
(Cul)3/Rbx1, so targeting the transcription factor for ubiquitinantion and proteasomal 
degradation. During oxidative stress or in response to electrophiles compounds, redox 
modification of cysteine residues in Keap1 protein happens, the Nrf2 ubiquitination is 
prevented, and the transcription factor is accumulated into nucleus activating 
transcription of nearly 500 genes, encoding for antioxidants, phase II enzymes and 
anti-inflammatory proteins (Fig. 3.5). On the other hand, activation of intracellular 
kinases, such as MAPK, PI3K or PKC, can in turn phosphorylate Nrf2, influencing 
cytosol-nucleus trafficking or Nrf2-nuclear stability 
179
. 
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Figure 3.5.  Nrf2/ARE pathway in the basal and induced state 
180
. 
 
 
Moreover, using FLIM-FRET-based system the researchers were able to study the 
dynamism of the Keap1-Nrf2 interaction in live cells 
181
. Data from this study 
revealed that in basal state Keap1-Nrf2 complex exists in two distinct conformations: 
an 'open conformation' in which only the EDGE (high affinity) motif bounds Keap1, 
and the 'closed conformation' where both EDGE and DLG motifs bound Keap1 
dimer. Deeping the dynamism behind what emerged is that in the basal state Nrf2 
protein first binds the free Keap1 through EDGE motif (open conformation) 
181, 182
, 
after this the closed conformation is formed through the binding between Nrf2 DLG 
motif and the other member of Keap1 dimer. Nrf2 in closed conformation is located 
in the orientation favoring ubiquitination by Keap1-dependet E3-ligase 
183, 184
, so 
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Nrf2 is released and degraded from proteasoma, and the free Keap1 can again bound 
a new Nrf2. 
Nrf2 is a protein that consist of 605 aa and possesses seven functional domains, 
denominated as Neh1-7 
185
. Neh1 has the bZip DNA binding and heterodimerization 
domain, and thanks to this domain Nrf2 can form the heterodimer with small Maf 
transcription factor. The heterodimer Nrf2/Maf is responsible for binding to ARE 
sequence, localized on the promoter of cytoprotective genes. Neh2 domain is 
functional for Nrf2 binding to Keap1 protein, containing the motifs through which 
monomeric Nrf2 binds the dimeric Keap1, named 'DLG' and 'ETGE' motif 
181
. Neh3 
domain binds to a Nrf2 co-activator, the chromo-ATPase/helicase DNA binding 
protein family member CHD6 
186
. Neh4 and Neh5 domains synergize to bind CBP, 
another Nrf2 co-activator 
187
. Other negative regulatory domains are Neh6, which 
mediates Keap1-indipendent Nrf2 degradation 
188
, and Neh7 that is responsible for 
Nrf2 interaction with retinoid X receptor alpha 
189
.  
On the other side, Keap1 is a 624 aa protein containing 
181
: 
 a N-terminal region; a BTB domain that allow Keap1 to do a homodimer and to 
interact with Cul3; an intervening region, the cysteine-rich domain; the Kelch domain 
useful for Nrf2 binding; and the C-terminal region.  
Regarding the Nrf2 export from the nucleus, the phosphorylation of Tyr568 by the 
kinase FYN, which is in turn activated by glycogen synthase kinase 3β (GSK-3β) 
lead to a strong binding with the nuclear exporting protein CRM1 
188
. Another 
mechanism is the binding between Nrf2 and the E3 ubiquitin ligase β-TrCP 
(βtransducing repeat-containing protein) via the Nrf2 Neh6 domain, which can be 
phosphorylated by GSK-3β, leading to Cullin 1 (Cul1)-dependent ubiquitination and 
degradation of Nrf2 via a Keap1-independent way 
177, 188. In turn, GSK3β can be 
inhibited through phosphorylation, which can be catalyzed by Akt, ERK and PKC 
kinases. 
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3.3 Oxidative stress and CVD 
 
Several are the cardiovascular sources of ROS. Level and activity of xanthine 
oxygenase are increased in heart failure as well as that of NAD(P)H oxidase 
154, 190
.  
The implication of ROS in the pathogenesis of CVD is particularly prominent in 
endothelial dysfunction, where the vascular microenvironment is altered. Vascular 
endothelium plays an active role in several mechanisms, such as regulation of 
vascular tone, inflammation, thrombosis, platelet activity and atherosclerosis 
154
. 
Substances like NO, endothelins, and prostacyclins are crucial in the maintenance of 
endothelium tone 
191
. The reduction in NO bioavailability leads to endothelial 
dysfunction promoting platelet adhesion and aggregation.
154
.  
Several mechanisms are implicated in the reduction of NO levels, including increased 
degradation, altered functionality of eNOS, reduced expression of eNOS 
192
. 
Furthermore ROS levels influences NO bioavailability, because ROS can oxidize NO 
to ONOO
- 
and tetrahydrobiopterin to dihydrobiopterin, so leading to eNOS 
dysfunction and further ROS release 
191
. As proof of NO importance for endothelial 
health, the up-regulation of hydrobiopterin and as consequence, NO amount, has been 
shown to improve endothelial function and decrease superoxide production 
193
.  
Vascular oxidative stress has also been linked to hypertension in several animal 
models 
194-196
. Patients with essential hypertension, renovascular hypertension, 
malignant hypertension and pre-eclampsia showed an increased ROS yield 
197-199
. 
ROS production has been evidenced in different types of vascular cells as endothelial, 
adventitial and vascular smooth muscle cells, mainly derived from NAD(P)H oxidase 
activity
200
. The effects of some pharmaceutical agents (for example angiotensin 1 
receptor blockers) acting on cardiovascular system have been attributed to their direct 
inhibitory activity on NAD(P)H oxidase enzyme. In addition, the outputs of more 
common antihypertensive agents (ACE-inhibitors, Ca
2+ channel blockers, β-
adrenergic blockers ecc.) could be related to their capacity to diminish vascular 
oxidative stress 
201-203
.  
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As mentioned before oxidative stress leads to endothelial dysfunction so affecting 
CVD incidence. In this context, ROS can induce a direct injury modifying cellular 
components, altering key proteins for contraction and diminishing NO availability 
204
.  
During myocardial ischemia, the amount of ROS produced in the reoxygenation step 
is the crucial cause of the reperfusion injury, and they can damage directly cellular 
constituents or indirectly through the induction of local inflammation 
205
. Moreover 
ROS can influence and alter several cellular pathways so modifying cellular function 
206
. For example, H2O2 has been shown to activate the protein kinase Akt in VSMC, 
leading to hypertrophy 
207
; in cardiomyocytes H/R induces activation of p38 and JNK 
pathways, involved in apoptotic cellular death 
208
. 
 
 
3.4 Sex-gender differences in oxidative stress 
 
The importance to deepen potential sex-gender differences in oxidative stress starts 
from the assumption that oxidative stress is implicated in many diseases with 
incidence, prevalence, symptoms, severity and outcomes that differ in males and 
females. Unfortunately, few studies have investigated the differences in oxidative 
stress or antioxidant defenses due to sex-gender.  
Biomarkers for oxidative stress were reported to be higher in young men than in 
young women 
209
. Likewise using vascular cells derived from men or women, the 
susceptibility to oxidative stress was greater in those from men 
210
. Data from clinical 
and experimental studies evidenced a more pronounced antioxidant capability in 
females than males 
211
. 
Differences in expression and activities of antioxidant enzymes were analyzed in 
males and females. Regarding SOD activity, one study showed a higher activity in 
female hearts but other investigations did not show uniform results, however it has 
been proposed that the differences depend on the tissue 
209, 212-214
. In animals, SOD 
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levels decreased after castration so implicating a role for sex hormones in the 
regulation of SOD activity 
212
. 
Catalase activity was found to be similar in both sexes as analyzed in different tissues 
213, 215
, so suggesting that H2O2 detoxification from catalase is not affected by gender 
or sex hormones. 
Several studies confirmed a minor activity for GPx enzyme in females 
209, 212, 213
, and 
no significant changes in males and females after castration 
212
. 
On the other side analyses of the NADPH-oxidase levels, guilty of the great 
production of superoxide, showed discrepancies between sexes.  
Different studies were consistent in showing a higher expression of Nox1 and Nox4 
in males than females, which can explain the differences in superoxide levels 
between sexes 
216-218
. At the same time, no differences were evidenced for Nox2 or 
the three isoforms of SOD (SOD1, SOD2, SOD3) 
216, 217, 219
. It seems that the greater 
basal oxidative stress seen in men could be mainly due to a higher superoxide 
production rather than a minor rate of detoxification. 
Apart from this, the major differences in antioxidant properties between males and 
females could be attributed to the antioxidant action of E2. It can act as scavenger of 
free radicals thanks to the presence of a phenolic hydroxyl group 
212
. Moreover E2 
also demonstrated to increase the gene expression of SOD2 via MAP-kinase 
signaling pathway 
220
. Oxidative stress level was also analyzed in pathological 
conditions. 
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Figure 3.6. Chemical structure of 17β-estradiol  
 
 In spontaneously hypertensive rats, males had higher superoxide levels than females 
due to a higher NADPH-oxidase activity, and, in line with this, males demonstrated 
lower levels of NO because it was degraded by superoxide 
221
. A study on coronary 
artery disease comparing men and post-menopausal women showed that the post-
menopausal group women had oxidative stress level almost three times higher than 
men 
222
. Furthermore, it has been shown that ovariectomyzed females have an 
increase in  NADPH-oxidase activity and treatment with E2 led to normal levels 
216
. 
This suggests a role for the hormone in mediating NADPH-oxidase activity.  
In conclusion, what emerged from these studies is that sex-gender differences in 
susceptibility to oxidative stress are principally due to a higher production of reactive 
species rather than a low antioxidant levels, and E2 seem to have a role in the 
orchestration of cellular redox balancing.  
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4.SULFORAPHANE AND CARDIOVASCULAR DISEASE  
 
 
4.1 Glucosinolates 
 
In the XIX century the first glucosinolate has been isolated from Sinapis alba 
223
. 
Later more than 120 different glucosinolates were described, mainly derived from 
plants belonging to Brassicaceae 
224
. 
The family of Brassicaceae includes more than 350 genera and over 3000 species. 
Common edible plants from this family are: broccoli, brussels sprouts, cabbage, 
capers, cauliflower, mustard, radishes. 
The pungent taste of these vegetables is due to the reaction products of myrosinase 
enzyme. 
 
 
 
 
Figure 4.1. Glucosinolate chemical structure. 
 
 
The glucosinolates are chemically a β-thioglucoside N-hydroxysulfate (Fig. 4.1) 225. 
Their basic structure includes a solphonated oxime, a β-D-thioglucose group, and a 
variable amino acidic side chain R, which can derive from methionine, phenyalanine, 
tryptophan or branched amino acids 
226
. In plants, the glucosinolates are associated, 
but physically separated, to β-thiogluosidase enzymes, known also as myrosinases 227. 
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Substrate and enzyme come in contact after plant cells injury (e.g. by chewing and 
cutting) and the consequence is a rapid hydrolysis with the release of glucose and 
instable aglycones, these last spontaneously rearrange into reactive compounds 
(Fig.4.2). In particular, all biological activities can be attributed to the glucosinolate 
hydrolysis products, and among these isothiocyanates are the most studied. Humans 
do not have myrosinase enzymes but glucosinolates can be converted into 
isothiocyanates thanks to gut microbiota. Reduction or abnormalities in the 
gastrointestinal microbiota reduce the bioavailability of the isothiocyanates 
228
.  
 
 
 
 
 
Figure 4.2. Myrosinase reaction products. (a) Glucosinolate hydrolisis products. Depending on 
reaction conditions and glucosinolate side chain (R), a range of products can be formed. (b) 
Chemical structure of aromatic isothiocyanates with anticarcinogenic activity. (c) Chemical 
structure of isothiocyanate sulforaphane and its synthetic norbonilic derivates. 
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4.2 Sulforaphane 
 
Sulforaphane (SF) (1-isothiocyanate-(4R)-(methylsulfinyl) butane) 
229
 derives from 
the hydrolysis of glucoraphanin, the main glucosinolate presents in broccoli (Fig 4.3) 
230, 231
. It is the most studied and well described isothiocyanate present in 
Brassicaceae 
232
. 
In particular, SF induces phase II enzymes 
233
, demonstrating efficacy in a range of 
cell lines. This group of enzymes, also known as drug-metabolizing enzyme, are 
responsible for detoxifying electrophiles and oxidants. Examples of enzymes 
belonging to this group are GST, GR and NQO1. Moreover, the Nrf2/ARE pathway 
has been demonstrated and widely studied as principal mechanism for SF 
bioactivities, which in turn up-regulate antioxidant and phase II enzymes expression 
233
. 
 
 
 
Figure 4.3. Schematic reaction between glucoraphanin and myrosinase. Modified from 
234
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4.3 Sulforaphane bioavailability 
 
The isothiocyanates in humans are metabolized through the mercapturic acid 
pathway. In the human studies, the first critical step was the identification of 
analytical instruments able to quantify and identify the isothiocyanates and their 
metabolites. All together they can be quantified by 1,2 benezenedithiol-based 
cyclocondensation 
235
 or individually by liquid chromatography coupled with mass 
spectrometry 
236
, and these instruments were used in pharmacokinetics studies. A 
study that compared a high dose (52 µmol) versus a low dose (16 µmol) of SF 
237
 
showed a rapid increase in SF and its metabolite plasmatic concentrations, with the 
maximum peak at 1.5 h and 2 h for low and high dose, respectively. The AUC (area 
under the curve) and maximum concentration (Cmax) resulted to be dose-dependent, 
with the Cmax of 2.2 ± 0.8 µM and 7.3 ± 2.9 µM for low and high dose, respectively. 
Shapiro et al. carried out a phase I clinical study to evaluate security, tolerance, and 
pharmacokinetics of broccoli sprout extracts containing glucosinolates or 
isothiocyanates. The study demonstrated absence of toxicity and high variability in 
glucosinolate metabolism. The participants were divided into four groups: placebo; 
25 µmol of glucosinolates; 100 µmol of glucosinolates; 25 µmol of isothiocyanates. 
The analysis of 32 different markers, including those for thyroid (TSH, T3, T4) and 
hepatic functionality (transaminases), did not evidence systemic adverse effects. The 
dithiocarbamates total excretion was (expressed as dose fraction) 17.8 ± 8.6% e 11.7 
± 19.6% for low and high dose of glucosinolates, respectively, finding a high 
interindividual variation. In the group who received isothiocyanates, the total 
excretion was 70.6 ± 2.0%, with few interindividual variation 
228
.  
These and other studies 
238-240
 clearly point out that the intake of glucosinolates, rather 
than isothiocyanates, is associated with lower bioavailability, slower excretion and 
more interindividual variation. The most likely cause in interindividual variations is 
the interconversion of the glucosinolates to isothiocyanates by gut microbiota, as also 
evidenced by Li et al., supporting the importance of gut microbiota in the degree of 
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glucosinolates hydrolysis 
241
. Atwell et al. suggested that another factor influencing 
SF absorption could be the food matrix and meal composition. Whole broccoli 
sprouts contain minerals, nutrients and phytochemicals that could enhance SF 
transport through cellular membranes. Therefore, raw sprouts have more fiber, 
slowing gut transit and increasing the contact time with gut epithelium surface 
239
. 
 
 
4.4 Nrf2/ARE pathway and sulforaphane 
4.4.1 Sulforaphane direct effects 
 
The central carbon in the isothiocyanate group of SF is electrophilic and can react 
with the cysteine residues present in Keap1 protein. It has been evidenced that SF is 
able to directly interact with critical Keap1 cysteine residues, blocking Nrf2 
ubiquitination and degradation and increasing Nrf2 translocation to the nucleus 
242
. 
In particular, C151 has been implicated as one of the site responsible for SF effects. 
Indeed, when C151 was mutated to a Ser, the induction of Nrf2 by SF was repressed 
243
. C151 residue involvement was also confirmed by other groups using a biotin-
switch technique and again mutagenesis experiments 
244
. Studies with mass-
spectrometry approach evidenced that, depending on the experimental conditions, 
besides C151 other residues can be involved in SF-Keap1 interaction 
245, 246
. Baird et 
al., with their FILM-FRET findings, hypothesized that inducers such as SF tend to 
stabilize Nrf2 in the closed conformation 
181
. In particular, SF interaction with 
cysteine residues, that leads to a conformational change of Keap1-Nrf2 complex, may 
alter the positioning of Nrf2 in respect to the ubiquitination machinery so that it can 
no longer be ubiquitinated and targeted for proteosomal degradation. However, in this 
conformation Nrf2 is not released from Keap1, so acting as a suicide substrate to 
inactivate Keap1 and new free Keap1 is not regenerated. The newly synthesized Nrf2 
will not find free Keap1 for its cytoplasmic sequestration, so it can translocate to the 
nucleus and activate gene transcription. This hypothesis can also explain how in 
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absence of new translation, using a translation inhibitor, also in presence of inducers, 
Nrf2 did not induce cytoprotective genes expression 
247-249
. 
 
 
4.4.2 Sulforaphane indirect effects 
 
Different kinases can modulate Nrf2/ARE pathway, including MAPK, PKC and 
PI3K 
250
. SF demonstrated to activate a variety of intracellular kinases, which in turn 
phosphorylate Nrf2, influencing cytosol-nucleus trafficking or Nrf2-nuclear stability 
250, 251
. Indeed, Kensler et al. demonstrated that phosphorylation of Nrf2 at serina 40 
can potentiate its activation 
252
.  
Leoncini et al. deepened the mechanism involved in SF effects using neonatal rat 
cardiomyocytes 
253
. The results evidenced SF-mediated increasing in Akt and ERK 
1/2 phosphorylation, which are kinases implicated in cardiac proliferation and 
survival. These kinases in turn augmented Nrf2 activation and ARE binding. The use 
of specific kinase-inhibitors showed the involvement of PI3K/Akt pathway in SF-
mediated cytoprotective genes induction via Nrf2/ARE pathway. 
 
 
4.4.3 Induction of long-term effects 
 
As mentioned before in this chapter, the ingestion of broccoli or SF leads to a peak in 
plasmatic concentration after few hours, with a rapid clearance from the body. 
However, several studies evidenced that SF can induce long-term protective effects 
against oxidative injury. In an astrocyte cellular model, a 4 h treatment with SF 
triggered an increase in mRNAs of HO-1 and NQO1 up to 24 h later, with the levels 
of the corresponding proteins elevated up to 48 h 
254
. Bai et al. treated diabetic mice 
with SF for three months and showed as the treatment was able to reduce the 
incidence of diabetic cardiomyopathy at the end of the treatment and also after six 
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months 
255
. Angeloni et al. also showed as SF treatment can cause long-term 
protection against oxidative stress, reducing the levels of intracellular ROS and DNA 
fragmentation and increasing the expression of cytoprotective enzymes in neonatal 
rat cardiomyocytes 
256
. 
 
 
4.5 Sulforaphane in Hypertension 
 
As mentioned in the previous chapter, oxidative stress has been demonstrated to play 
a key role in the etiopathogenesis of hypertension.  
In an animal model of spontaneously hypertensive rats, diet containing broccoli 
sprouts high in glucoraphanin was able to decrease oxidative stress. Moreover,  SF, 
the main glucoraphanin derivative,  demonstrated to improve blood pressure 
257
. In 
vascular smooth muscle cells derived from hypertensive rats, SF-treatment (0.05-1 
µM) reduced oxidative injury up-regulating phase II enzyme, increasing basal level 
of reduced glutathione. These changes have been correlated with an improved 
endothelial relaxation and blood pressure 
258, 259
. 
 
 
4.6 Sulforaphane in Atherosclerosis  
 
Atherosclerosis represents an important risk factor for CVD. It is usually associated 
with a chronic inflammation status in the arterial wall. Inflammation status increases 
the expression of cell adhesion molecules as intercellular adhesion molecule-1 
(ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1), both associated with an 
increase in VSMC proliferation. In several studies SF-treated VSMC (1-5 µg/mL) 
showed reduced mRNA and protein levels of cell adhesion molecules, after exposure 
to an inflammatory cytokine as TNF-α, and so suppressing inflammation within the 
atherosclerotic lesion 
260-262
. 
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It is well known that an important factor for the development of atherosclerosis is the 
plasmatic level of cholesterol and in particular its distribution between HDL and LDL 
cholesterol. Endothelial lipase is an enzyme belonging to the triacylglycerol family 
and it is responsible for the reduction in HDL levels. Two different studies carried out 
in HUVEC cells, indicated SF as a powerful agent in contrasting cholesterol level 
alterations at endothelial site. In particular SF was able to reduce the increase TNF-
induced of endothelial lipase 
263
, and to counteract oxidative injury induced by 
oxidized-LDL, increasing the expression of HO-1 and GSH content 
264
. 
Platelet aggregation plays a role in the incidence of atherosclerosis, and the potential 
effects of SF were investigated. SF demonstrated to inhibit human platelet 
aggregation in a dose-dependent manner preventing the activation of PI3K-Akt 
pathway 
265, 266
. SF showed to clearly decrease glycoprotein IIb/IIIa activation and 
thromboxane A2 formation 
266
. 
 
 
4.6 Sulforaphane in cardiac Ischemia/Reperfusion injury 
 
I/R injury is well known to be associated with the pathology of important CVD such 
as stroke or heart attack 
267
. The damage that can occur in the two phases, ischemia 
and reperfusion, is often irreversible for cells or tissues. However, a third phase of 
this pathological process exists, which is the post-reperfusion phase when tissue 
remodeling and adaptation occur. Increased ROS levels seem to play a key role in all 
these phases 
267
. Cardiomyocytes treated with SF (0.1-5 µM) and then subjected to 
I/R injury showed improved cellular viability and Bcl2/Bax ratio associated with 
increased SIRT1 expression and reduced cellular apoptotic death and expression of 
endoplasmic reticulum stress-related apoptosis proteins. SF-containing broccoli 
provided cardioprotective effects against I/R injury, ameliorating post-ischemic 
ventricular function and reducing the myocardial infarct size, in rats 
229, 268
. These 
effects were associated with higher Nrf2 activity. Regarding cardiac remodeling, SF 
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demonstrated to reduce fibrosis and to induce a favorable redox environment 
(increased HO-1) switching the kinase balance toward pro-survival kinases (ERK 1/2 
and Akt) so mitigating the progression of cardiac remodeling after the infarction.   
 
 
4.7 Sulforaphane protection from Diabetes complications 
 
Diabetes pathology reached an epidemic characteristic worldwide. Diabetic patients 
are prone to develop CVD and the diabetic complications involve micro- and 
macrovascular impairment. The most common diabetic complications include 
retinopathy, neuropathy, nephropathy, diabetic cardiomyopathy. A chronic high-
glucose status is linked with an increased production of ROS and all contribute to 
oxidative and inflammatory damage, increasing the possibility to develop a diabetes 
complication.  
In diabetic nephropathy, which results in premature death associated with CVD and 
kidney collapse, SF helped to counteract the pathological deficits thanks to its 
antioxidant and antinflammatory activities, with a dual behavior on Nrf2 and NF-kB 
269
. In experimental model of streptomycin-induced nephropathy, SF ameliorated 
renal function and metabolic indices, but only in animals with functional Nrf2/ARE 
pathway, indicating a key role of this pathway 
270
. Streptomycin-induced diabetic 
type I was associated with increased ROS and inflammation which led to fibrotic 
response after 6 months of diabetes. In this model SF completely reversed diabetes-
induced changes 
271
. 
Diabetic cardiomyopathy is the complication which account the most deaths for 
diabetes 
272
. Researchers investigated whether SF can prevent cardiomyopathy in 
different diabetic models. In db/db type II diabetic mice, administration of SF (0.5 
mg/kg) or a high dose of broccoli sprout extracts (equivalent to 1 mg/kg) prevented 
hypertrophy, cardiac dysfunction and fibrosis diabetes-induced, and the effects were 
associated with an improved Nrf2 activity 
273
. Also in a model of high-fat diet-
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induced type II diabetes mellitus, SF demonstrated to prevent lipid accumulation, 
significantly improving cardiac function, fibrosis, oxidative stress and inflammation 
274
. 
 
 
4.8 Conclusion 
 
Oxidative stress plays a pivotal role in contributing to the development of cardiac 
pathologies. SF is an isothiocyanate found in edible brassica vegetables, which 
demonstrated to act as an indirect antioxidant. The main mechanism related to SF-
induced protective effects is the activation of Nrf2/ARE pathway and its downstream 
target genes. Bioavailability studies evidenced that its absorption can be influenced 
by dietary form, i.e. fresh broccoli sprouts (myrosinase-active) showed the highest 
bioavailability rather than broccoli with inactive myrosinase (as example broccoli 
overly cooked). Regarding the amount of SF that should be achieved for CVD 
prevention, it has been demonstrated that 5 µM SF protects cardiomyocytes from 
oxidative damage and that 2.8 µmol/kg of SF prevents CVD in diabetic mice. If we 
applied the conversion formula between animals and humans 
275
, a man with body 
weight of 70 kg is supposed to consume a SF dose of 19.6 µmol per day, i.e. 12 g per 
day of fresh broccoli. This is much lower than the dosage used in studies for cancer 
prevention (150 µmol per day) which showed no toxic effects 
236, 276
.  
In conclusion, diet habits containing Brassicaceae as source of SF could be helpful in 
the prevention of CVD. The amount of SF which showed cardioprotective effects is 
easily achievable. However, it could be opportune to perform clinical trials to clarify 
the effects and the optimal dose for SF in the prevention of CVD. 
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5. AIM 
 
 
Cardiovascular disease continues to be the most common cause of death worldwide 
1
. 
Several studies demonstrate as women with myocardial infarction have a better 
prognosis than men 
277-279
, but this difference is reversed after menopause 
280
. 
Furthermore, the development of coronary artery disease occurs ten year later in 
women than men 
2
. Thus, it has been suggested that sexual steroid hormones can play 
a role in the protection from CVD in women, so implying a sex-gender dependent 
effect. 17β-estradiol (E2) is the principal female estrogen, major product of ovary 
secretion, which owns the strongest potency and has the capability to bind all 
subtypes of estrogen receptors. It has been demonstrated that E2 provides protection 
on bone density, central nervous and cardiovascular system 
281
. Regarding 
cardioprotection, in several studies it has been investigated the potential role of E2 in 
cardiac cell survival against different insults. E2 reduces cardiomyocytes apoptosis in 
vivo and in vitro through estrogen receptors and phosphoinositide-3-kinase 
(PI3K)/Akt signaling pathways 
25, 26
. In cardiomyocytes, E2 is also able to differently 
modulate prohypertrophic (class I) and antihypertrophic (class II) histone deacetylase 
proteins through the binding to ERβ, thus counteracting cardiac hypertrophy 28. 
Short-term treatment with E2 has shown to be able to improve heart function after I/R 
injury, and using a NOS inhibitor this effect was reversed, so suggesting the 
contribution of NO production via ER activation in this process 
85
.  
It has also been shown that sex-gender can influence the pharmacokinetics and 
pharmacodynamics of a drug 
2
, and as a consequence it can influence the response to 
cardiovascular medications 
4, 282, 283
. In this context, we hypothesized that sex 
hormones could also differently influence the preventive/protective effects of 
nutraceutical compounds in males and females. To the best of our knowledge no 
studies have been carried out to test this hypothesis. 
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Among nutraceutical compounds, sulforaphane has been highly investigated for its 
anticancer activity 
284
. Sulforaphane is a dietary isothiocynate, mainly found in 
brassica vegetables, produced after the breakdown of its precursor glucoraphanin. 
Recently it has been reported that SF has got cardioprotective activity in different in 
vitro and in vivo models 
285-287
. The main mechanism involved in SF protective 
effects is the activation of Nrf2/ARE signaling pathway 
253
 and consequently the up-
regulation of the antioxidant defense system. SF elicits many other biological 
activities beyond the antioxidant effects, as anticancer, anti-inflammatory, 
antiglycative and neuroprotective properties 
284, 288-291
.  
 
Aim of this PhD thesis was to explore the modulatory effect of E2 on the 
cardioprotective activity of SF against oxidative stress in primary cultures of rat 
cardiomyocytes against oxidative stress by analyzing antioxidant/survival 
pathways and investigating the involvement of ERs and GPR30. 
 
Part of this thesis was conducted in the Institute of Gender in Medicine-Charité-
Universitätsmedizin, in Professor Vera Regitz-Zagrosek’s laboratory in Berlin. 
 
As experimental model we used primary cultures of rat cardiomyocytes and rat 
cardiomyoblast cell line. Cells were pre-treated with SF (0.1-5 µM) and/or E2 (10-
500 nM) and oxidative stress was induced exposing cells to 100 µM of H2O2. We 
evaluated cell viability by MTT and LDH assays, oxidative stress injury by DCFH-
DA assay and immunofluorescence staining, glutathione levels by MCB assay, 
antioxidant/phase II enzymes, Nrf2 and ERs gene expression by RT-PCR, Nrf2 
activity by ELISA-based kit and Western Blotting, and the phosphorylation of ERK 
1/2 and Akt kinases by Western Blotting. 
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6. MATHERIALS AND METHODS  
 
 
6.1 Chemicals  
 
PhosSTOP was purchased from Roche Diagnostics (Mannheim, Germany). 3-(4,5-
dimethylthiazol-2-yl)-2,5diphenyl-tetrazolium bromide (MTT), 2,7-
dichlorodihydroﬂuorescein diacetate (DCFH-DA), H2O2, dimethyl sulfoxide 
(DMSO), monochlorobimane (MCB), phosphate-buffered saline (PBS), bovine 
serum albumine (BSA), Dulbecco’s modiﬁed Eagle’s medium (DMEM) F-12, 
DMEM, fetal calf serum, horse serum, Charcoal-stripped fetal calf serum, 
gentamicin, sodium pyruvate, inositol, amphotericin B, collagenase IA, 17β-estradiol 
(E2), LY294002 (LY), PD98059 (PD), 1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-
piperidinylethoxy)phenol]-1H–pyrazoledihydrochloride hydrate (MPP), 2-phenyl-3-
(4-hydroxyphenyl)5,7-bis(triﬂuoromethyl)-pyrazolo[1,5-a]pyrimidine,4-[2-phenyl-
5,7-bis(triﬂuoromethyl)pyrazolo[1,5-a] pyrimidin-3-yl] phenol (PHTPP), sodium 
fluoride, sodium pyrophosphate, sodium orthovanadate, methylglyoxal (MG) and all 
other chemicals of the highest analytical grade were purchased from Sigma Chemical 
(St. Louis, MO, USA), unless otherwise stated. 4,4',4''-(4-Propyl-[1H]-pyrazole-
1,3,5-triyl)trisphenol (PPT) and (±)-1-[(3aR*,4S*,9bS*)-4-(6-Bromo-1,3-
benzodioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinolin-8-yl]- ethanone 
(G1) were purchased from TOCRIS (Wiesbaden-Nordenstadt, DE). KB5 were kindly 
provided from Novartis (Cambridge, MA, USA). E2 was dissolved in DMSO at a 
concentration of 10 mmol/L and kept at –20 °C until use. D,L-sulforaphane (SF) 
(LKT Lab., Minneapolis, Minn., U.S.A.) was dissolved in DMSO at a concentration 
of 10 mmol/L and kept at –20 °C until use. 
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6.2 Cell cultures and treatments 
 
Primary cultures of neonatal Sprague-Dawley rat cardiomyocytes were prepared as 
previously described 
292
. The investigation conforms with the Guide for the Care and 
Use of Laboratory Animals published by the U.S. National Institutes of Health (NIH 
Publication 85-23, revised 1996) and approved by the Ethics Committee of our 
institution. Briefly, rats were sacrificed and the ventricles were placed in a special 
medium (946 mg /100 mL Ham-F10, 93 mM KH2PO4, 38.5 mM Na2HPO4, 14.2 mM 
NaHCO3 and 0.5 mM inositol) and finely minced. The special medium was then 
replaced with the trypsinization medium obtained by adding trypsin 10x (10% v/v) 
and collagenase IA (5% v/v) to the special medium (85%). Subsequently, tissue 
fragments were resuspended in complete medium (DMEM F-12 supplemented with 
10% (v/v) FBS, 10% (v/v) HS, 1mM sodium pyruvate, 0.1 mg/mL gentamicin and 
2.5 µg/mL  amphotericin B, in a ratio of 1 mL medium / 100 mg of initial tissue. The 
cell suspension were "pre-plated", after filtration, in T75 flasks. After the steps of 
"pre-plating", the cells were counted with a hemocytometer and plated at a 
concentration of 5x10
5
 cells / mL and incubated at 37 °C, 5% CO2, 95% humidity.  
Cells were treated, with different concentration (0.1-5 µM) of SF and with different 
concentration (10-500 nM) of E2 or co-treated with SF and E2 for 24 h. The control 
group were treated with an equivalent volume of the vehicle alone. Oxidative stress 
was induced by 100 μM H2O2 for 30 min or by 0.5 mM MG for 24 h. 
Rat embryonic cardiomyoblast-derived H9c2 cells were obtained from American 
Type Culture Collection (ATCC, Rockville, MD). Cells were cultured in Dulbecco’s 
modified Eagle’s medium (DMEM, glucose content 5.5 mM) supplemented with 
10% FBS, 2.5 mM glucose, 21.4 mM bicarbonate and a combination of penicillin and 
streptomycin (1%) in a humidified 5% CO2 atmosphere at 37 °C. For all experiments, 
cells were plated at an appropriate density according to the experimental design. 
Before treatments, cells were starved with 3% charcoal stripped FBS in phenol-red 
free media. Cells were treated with 0.5 µM SF and with 10 nM E2 or co-treated with 
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SF and E2 for different times (30 min, 2 h). For experiments with ER agonists, cell 
were treated with G1 (100 or 1000 nM), PPT (10or 100 nM) and  KB5 (10 or 100 
nM). The control group was treated with an equivalent volume of the vehicle alone. 
 
 
6.3 Cell viability and Lactate Dehydrogenase Activity Assays 
 
Cell viability was evaluated by measuring MTT reduction, as previously reported (2). 
Brieﬂy, at the end of each experiment, 0.5 mg/ml MTT were added and incubated for 
1 h at 37°C. After incubation, MTT solution was removed, 200 µl DMSO were 
added, and the absorbance was measured at λ=595 nm using a microplate 
spectrophotometer (VICTOR3 V Multilabel Counter; Perkin-Elmer, Wellesley, MA, 
USA). Lactate dehydrogenase (LDH) activity was evaluated in the culture medium 
using the Lactate Dehydrogenase Activity Assay Kit (SIGMA) according to the 
manufacturer's instructions. Data are reported as percentage of control cells. 
 
 
6.4 Immunoﬂuorescence Staining 
 
Cells were seeded on glass coverslips, and at the end of each experiment, 
cardiomyocytes were washed twice with PBS, ﬁxed with 3% paraformaldehyde, 
washed with 0.1 M glycine in PBS and permeabilized in 70% ice cold ethanol. After 
ﬁxing, the cells were incubated with anti-8-hydroxy-2′-deoxyguanosine (8-OHdG) 
(StressMarq Biosciences, Victoria, CA, USA) or anti-Nrf2 (Santa Cruz 
Biotechnology, Santa Cruz, CA, USA) overnight at 4°C. Subsequently, the samples 
were washed with 1% BSA in PBS and incubated with CY3- or FITC-conjugated 
secondary antibodies for 1 h at room temperature. DAPI was used for labeling nuclei. 
Preparations were embedded in Mowiol, and images were acquired using an Axio 
Scope A1 microscope (Zeiss, Oberkochen, Germany).  
~ 59 ~ 
 
6.5 Intracellular ROS production assay 
 
Intracellular ROS levels were evaluated using the ﬂuorescent probe DCFH-DA, as 
previously reported 
293
. At the end of each experiment, cardiomyocytes were 
incubated with 10 μg/ml DCFH-DA in PBS for 30 min. After removal of DCFH-DA, 
cells were exposed to 100 μM H2O2 in PBS for 30 min. Cell ﬂuorescence was 
measured using 485-nm excitation and 535-nm emission with a microplate 
spectroﬂuorometer (VICTOR3 V Multilabel Counter, Perkin-Elmer). Data are 
reported as percentage of H2O2-treated cells. 
 
 
6.6 Reduced Glutathione levels 
 
Glutathione (GSH) levels were determined with a ﬂuorimetric assay as previously 
reported 
289. Brieﬂy, at the end of each experiment, culture medium was removed, and 
cardiomyocytes were washed and incubated for 30 min at 37°C in fresh PBS 
containing 50 μM MCB. After incubation, ﬂuorescence was measured at 355 nm 
(excitation) and 460 nm (emission) with a microplate spectroﬂuorometer (VICTOR3 
V Multilabel Counter, Perkin-Elmer). Data are reported as percentage of control. 
 
 
6.7 Western Blotting  
 
Preparation of nuclear and cytoplasmic fractions was performed according to the 
method of Bahia et al. 
294
. Briefly, cells were washed with ice-cold PBS and lysed on 
ice using a buffer composed of 10 mM HEPES, 1.5 mM MgCl2, 10 mM KCl, 2.5 
mM EDTA, 2 mM EGTA and 0.05% NP4O containing mammalian protease 
inhibitors. The lysates were centrifuged at 1000 g for 5 min at 4°C and at 2000 g for 
further minute. The supernatant containing the cytoplasmic fraction was taken off and 
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the remaining pellet was resuspended in 100 μL of a buffer comprising: 5 mM 
HEPES, 1.5 mM MgCl2, 0.2 mM EDTA, 0.5 mM dithiothreitol, 300 mM NaCl and 
26% v/v glycerol. Samples were homogenized and centrifuged at 15 000 g for 20 
min. The supernatant containing the nuclear fraction was retained. For evaluation of 
protein kinases phosphorylation, after treatments, cells were collected and 
homogenized in radioimmunoprecipitation assay  (RIPA) buffer with a mammalian 
protease inhibitor mixture and PhosSTOP.  
Samples were boiled for 5 min prior to separation on 4%–20% MiniPROTEAN TGX 
Precast Protein Gels (BIO-RAD, Hercules, CA, USA). The proteins were transferred 
to a nitrocellulose membrane (Hybond-C; GE Healthcare, Buckinghamshire, UK) in 
Tris-glycine buffer at 110 V for 90 min. Membranes were then incubated in a 
blocking buffer containing 5% (w/v) skimmed milk and incubated with anti-phospho-
ERK1/2, anti-ERK1/2, anti-phospho-Akt, anti-Akt (Cell Signaling Technology, 
Beverly, MA) and anti-Nrf2, anti-lamin A (Santa Cruz Biotechnology, Santa Cruz, 
CA, USA) and anti-β-actin (SIGMA), as internal normalizers, overnight at 4°C on a 
three-dimensional rocking table. The results were visualized by chemiluminescence 
using Clarity Western ECL reagent according to the manufacturer's protocol (BIO-
RAD). Semiquantitative analysis of speciﬁc immuno-labeled bands was performed 
using a ImageLabTM 5.2 Software (Bio-Rad, Hercules, CA). 
 
 
6.8 Analysis of the Nrf2-ARE binding activity  
 
After cellular treatments, nuclear extracts were prepared using a Nuclear Extraction 
Kit (Active Motif, Carlsbad, Calif., U.S.A.) according to the manufacturer's 
instructions. Nrf2 binding activity to ARE was measured in nuclear extracts using a 
TransAM™ Nrf2 Kit (Active Motif, Carlsbad, Calif., U.S.A.) following the 
manufacturer's recommended protocol. Briefly, nuclear extracts were added to a 96 
well plate coated with double-strand oligodeoxynucleotides containing the ARE 
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consensus binding site (5′-GTCACAGTGACTCAGCAGAATCTG-3′). A primary 
antibody against Nrf2 (1: 1000), added to each well and incubated for 1 h, was 
detected by secondary horseradish peroxidase (HRP)-conjugated antibody, using a 
colorimetric substrate. The signal was recorded at 450 nm using a microplate reader 
xMarkTM (Bio-Rad Lab., Hercules, Calif., U.S.A.), and Nrf2-ARE binding was 
evaluated as optical density units at 450 nm and reported as fold increase in 
comparison to controls. 
 
 
6.9 RNA extraction 
 
After the treatments, total RNA was extracted using Absolutely RNA Miniprep Kit 
(Agilent Technologies, Palo Alto, CA), following the manufacturer's protocol. The 
yield and purity of the RNA were measured using NanoVue Spectrophotometer (GE 
Heathcare). The integrity of the RNA was determined using an Agilent 2100 
BioAnalyzer (Agilent, Willmington, DE). 
 
 
6.10 Analysis of mRNA expression by RT-PCR 
 
mRNA was reverse transcribed into cDNA starting from 1 µg of total RNA using 
iScriptTM cDNA Synthesis Kit (BIO-RAD), following manufacturer's protocol. The 
subsequent PCR was performed in a total volume of 20 µL containing 5 µL (25 ng) 
of cDNA, 10 µL (1x) SsoAdvancedTM Universal SYBR Green Supermix (BIO-
RAD), and 1 µL (500 nM) of each primer (SIGMA). The primers used are as follows. 
CAT 5' CAAGTTCCATTACAAGACTGAC (Forward) 3' 
TTAAATGGGAAGGTTTCTGC (Reverse),  NQO1 5' 
TAGCTGAACAGAAAAAGCTG (Forward) 3' GTCTTCTTATTCTGGAAAGGAC 
(Reverse),  SOD1 5' AATGTGTCCATTGAAGATCG (Forward) 3' 
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CACATAGGGAATGTTTATTGGG (Reverse), SOD3 5' 
AGGAATCCTTCACACCTATG (Forward) 3' GTCCTCAGAGTAAAAGGAGAG 
(Reverse), HO-1 5' CCTGGTTCAAGATACTACCTC (Forward) 3' 
ACATGAGACAGAGTTCACAG (Reverse), β-actin 
5′AAGACCTCTATGCCAACAC3′ (forward) 5′TGATCTTCATGGTGCTAGG3′ 
(reverse) and β2-microglobulin 5′ACTGGTCTTTCTACATCCTG3′ (forward) 
5′AGATGATTCAGAGCTCCATAG3′ (reverse) from Sigma. Another set of primers 
was purchased from Qiagen (Milano, Italy) and corresponded to the following 
catalog numbers: GPX-1, PPR45366A; GR, PPR46891B; GSTa3, PPR44866A; Trx, 
PPR51711A; GSTp2, PPR52644B GSTm1: PPR42787B. β-Actin and β2-
microglobulin were used as reference genes. The cDNA ampliﬁcation was started by 
activating the polymerase for 30 s at 95°C, followed by 40 cycles of 5 s at 95°C and 
30 s at 60°C. A melt curve was run to ensure quality control and the generation of a 
single product. Normalized expression levels were calculated relative to control cells 
according to the 2
−ΔΔCT
 method 
295
. 
 
 
6.11 Statistical analysis 
 
Each experiment was performed at least three times, and all values are represented as 
means ± SEM. One-way analysis of variance (ANOVA) was used to compare 
differences among groups followed by Bonferroni's test (Prism 5; GraphPad 
Software, San Diego, CA, USA). Values of p<0.5 were considered statistically 
signiﬁcant. 
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7. RESULTS 
 
 
7.1 E2-enhancement of SF protective effects against oxidative stress  
 
First aim of this project was to evaluate the potential protective effect of E2 and SF 
against oxidative injury. Cells were treated with  increasing concentrations of E2 (10-
500 nM) and SF (0.1-5 µM) and after 24 h cells were exposed to 100 μM H2O2 for 30 
minutes (Fig. 7.1) and the cellular viability measured by MTT assay. 100 μM H2O2 
for 30-min has been choosen as in previous studies it demonstrated to reduce cell 
viability of 50% in rat cardiomyocytes 
293, 296
. The pre-treatment with 0.5 µM, 1 µM 
and 5 µM SF induced protection against oxidative damage, increasing cell viability in 
respect to H2O2-treated cells (Fig. 7.1 A). In particular, 5 µM SF was able to maintain 
cell viability to level comparable to control cells, meanwhile 0.1 µM SF did not 
protect from oxidative injury. Differently, the pre-treatment with E2 did not show any 
protective effect against H2O2-induced damage (Fig. 7.1 B).  
To explore the possible effect of E2 on SF protective activity against oxidative stress 
we chosen the highest SF concentration that did not protect from oxidative stress (0.1 
µM) and the lowest SF concentration that showed efficacy against oxidative damage 
(0.5 µM) (Fig. 7.1 A). Noteworthy, these concentrations are easily achievable in 
plasma after broccoli intake 
239, 297
. Regarding E2 concentration, no concentration 
tested showed protective effects, so we decided to use physiological concentrations of 
the hormone (10 nM, 50 nM) 
298, 299
. Cardiomyocytes were treated with SF (with 0.1 
and 0.5 μM) in the absence or presence of E2 (10 and 50 nM). After 24 h cells were 
exposed to peroxide for 30 min and cell viability was evaluated by MTT assay (Fig. 
7.2 A) and LDH release (Fig. 7.2 B). The co-treatments with 0.5 μM SF and E2 was 
able to increase cell viability with respect to H2O2-treated cells. On the contrary, 0.1 
μM SF in the presence of E2 did not increase cell viability in respect to peroxide 
treated cells. 
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Figure 7.1. Effect of increasing SF and E2 concentrations against H2O2-induced oxidative stress in 
cardiomyocytes. Cells were treated with SF (0.1-5 µM) (A) and E2 (10-500 nM) (B) for 24h and exposed to 
100 µM H2O2 for 30 minutes. Cell viability was measured by MTT assay as reported in Materials and 
Methods. Each bar represents means±SEM of at least four independent experiments. Data were analyzed by 
one-way ANOVA followed by Bonferroni's test. *p<0.05 vs CTRL; °p<0.05 vs H2O2. 
 
 
A 
B 
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The co-treatment with 0.5 μM SF and 10 nM E2 was the most powerful to mitigate 
oxidative damage as it signiﬁcantly increased cell viability with respect to both H2O2- 
and 0.5-μM-SF-treated cells. Moreover, this co-treatment maintained cell viability to 
level comparable to control cells, suggesting that E2 strongly enhances SF protective 
effect against oxidative stress (Fig. 7.2 A). These results were confirmed by LDH 
release assay. The co-treatment with 0.5 μM SF and 10 nM E2 significantly reduced 
LDH release in respect to both H2O2- and 0.5-μM-SF-treated cells (Fig. 7.2 B).  
To investigate whether E2 can boost SF protective effects also against other oxidative 
injuries, cardiomyocytes were pre-treated with 0.5 μM SF in absence or presence of 
10 nM E2 and then exposed to 0.5 mM Methylglyoxal (MG) for 24 h (Fig. 7.3). 
MG is a dicarbonyl compound, by-product of glycolysis, and its ability to cause 
oxidative stress has been extensively reported 
300, 301
. In a previous paper this MG 
concentration was able to induce oxidative damage in cardiomyocytes 
302
. The 
treatment with 0.5 µM SF signiﬁcantly increased cell viability in respect to MG 
treated cells as measured by MTT assay (Fig. 7.3 A); on the contrary, E2 had no 
effect against MG-induced injury. In agreement with the data on the protection 
against H2O2, SF and E2 co-treatment signiﬁcantly increased cell viability in respect 
to both MG- and SF-treated cells, suggesting that E2 modulates SF ability to 
counteract also MG-induced oxidative damage. These results were confirmed by 
LDH release assay. The co-treatment signiﬁcantly reduced LDH release with respect 
to both MG and SF-treated cells (Fig. 7.3 B). 
As the co-treatment with 0.5 µM SF and 10 nM E2 was the most effective in 
counteracting oxidative stress, we chose these concentrations for the subsequent 
experiments. To deepen the mechanisms behind E2 ability to enhance SF 
cardioprotection against H2O2-induced injury, we investigated the potential 
modulatory effect of E2 on SF capability to reduce intracellular ROS levels in 
cardiomyocytes by the DCFH-DA assay. Cells were pre-treated with 0.5 μM SF in 
the absence/presence of 10 nM E2 and then exposed to 100 µM H2O2 for 30 min (Fig. 
7.4). 
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Figure 7.2. Effect of E2 on SF protective activity against H2O2-induced injury in cardiomyocytes. Cells 
were treated with SF (0.1 – 0.5 µM) in the absence/presence of E2 (10 – 50 nM). (A) Cell viability was 
measured by MTT assay as reported in Materials and Methods. (B) Cell damage was measured by LDH 
activity in the culture medium as reported in Materials and Methods. Each bar represents means ± SEM of 
at least 4 independent experiments. Data were analyzed by one-way ANOVA followed by Bonferroni’s test. 
*p <0.05 with respect to control; °p< 0.05 with respect to H2O2; §p< 0.05 with respect to SF 0.5 µM. 
 
 
 
A 
B 
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Figure 7.3. Effect of E2 on SF protective activity against MG-induced injury in cardiomyocytes. Cells 
were treated with 0.5 µM SF in the absence/presence of 10 nM E2.  (A) Cell viability was measured by MTT 
assay as reported in Materials and Methods. (B) Cell damage was measured by LDH activity in the culture 
medium as reported in Materials and Methods. Each bar represents means ± SEM of at least 4 independent 
experiments. Data were analyzed by one-way ANOVA followed by Bonferroni’s test. *p <0.05 with respect 
to control; °p< 0.05 with respect to H2O2; §p< 0.05 with respect to SF 0.5 µM+H2O2. 
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Figure 7.4. Effect of E2 on SF capability to reduce intracellular ROS levels in cardiomyocytes. Cells were 
pre-treated with 0.5 µM SF in absence/presence of 10 nM E2. Intracellular ROS levels were measured with 
the ROS-sensitive probe DCFH-DA as reported in Material and Methods. Data are expressed as percentage 
in respect to H2O2-treated cells. Each bar represents means ± SEM of  at least 4 independent experiments. 
Data were analyzed by one-way ANOVA followed by Bonferroni’s test. °p< 0.05 with respect to H2O2; §p< 
0.05 with respect to SF 0.5 µM. 
 
 
SF treatment signiﬁcantly reduced intracellular ROS production with respect to H2O2; 
meanwhile, E2 did not significantly modify ROS levels compared to H2O2. 
Interestingly, the co-treatment was the most effective in reducing ROS levels in 
respect to SF alone, in agreement with viability data. 
To validate the boosting effect on SF antioxidant ability elicited by E2 in 
cardiomyocytes, we evaluated the formation of 8-OHdG, a marker of oxidative 
damage to DNA (Fig. 7.5). The cells were plated in coverslips, treated with 0.5 µM 
SF in absence/presence of 10 nM E2 and then exposed to 100 µM H2O2 for 30 min. 
The coverslips were then fixed and stained with anti-8-OHdG antibody, as reported in 
Materials and Methods. Positive staining for 8-OHdG was nearly noticeable in the 
cytoplasm or nucleus of control and SF and/or E2-treated cardiomyocytes not 
exposed to peroxide. As expected, H2O2 triggered a strong positive staining for 8-
OHdG, meanwhile the pre-treatment with SF and/or E2 mitigated the positive 
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staining for 8-OHdG. In agreement with the data on viability, the co-treatment was 
the most effective in reducing the positive staining.   
As GSH is the main endogenous antioxidant involved in the maintenance of cell 
redox status, we investigated the effect of SF and E2 co-treatment on intracellular 
GSH levels by the MCB assay. Cells were pre-treated with 0.5 μM SF in the 
absence/presence of 10 nM E2 and then exposed to 100 µM H2O2 for 30 min (Fig. 
7.6). Peroxide signiﬁcantly decreased GSH levels with respect to control cells. E2 
was not able to restore GSH levels, meanwhile, both SF alone and the co-treatment 
were able to signiﬁcantly increase the amount of GSH with respect to H2O2, and to 
maintain it to a level comparable to control cells. 
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Figure 7.5. Effect of E2 on SF capability to contrast oxidative DNA injury in cardiomyocytes. Cells were 
pre-treated with 0.5 µM SF in absence/presence of 10 nM E2 and then exposed to H2O2 for 30 min. 
Intracellular oxidative DNA damage was detected using an immunofluorescence staining with anti-8-OHdG 
antibody as reported in Material and Methods. Images were acquired with a 100x objective. 8-OHdG: red 
fluorescence (Cy3); Nuclei: blue fluorescence (DAPI). 
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Figure 7.6. Effect of E2 and SF on GSH levels in cardiomyocytes. Cells were pre-treated with 0.5 μM SF in 
absence/presence of 10 nM E2 and then exposed to H2O2 for 30 min. GSH levels were assessed using the 
fluorescence probe MCB as reported in Material and Methods. Each bar represents the mean ± SD of 4 
independent experiments. Data were analyzed by one-way analysis of variance (ANOVA) followed by 
Bonferroni’s test. *p < 0.05 with respect to control; °p < 0.05 with respect to H2O2. 
 
 
7.2 Effect of E2 and SF on Nrf2 and phase II enzymes  
 
It has been extensively reported that SF is a strong phase II enzyme inducer 
256
, so we 
next examinated the potential modulatory effect of E2 on SF ability to up-regulate 
phase II enzymes and the related transcription factor, Nrf2. In particular, we 
investigated the expression of GSTM1, GSTp2, GSTa3, HO-1, GR, CAT, NQO1, 
TrxR1, SOD1, SOD3, GPX and Nrf2. Cells were treated with 0.5 μM SF in the 
absence/presence of 10 nM E2, and after 24 h the RNA has been extracted, reverse 
transcribed into cDNA and mRNA levels analyzed by RT-PCR. 
As reported in Fig. 7.7, SF alone signiﬁcantly up-regulated GSTM1, GSTp2, GSTa3, 
GR, CAT, NQO1 and TrxR1 with respect to control cells, meanwhile it did not 
modulate the expression of HO-1 and Nrf2. On the contrary, the co-treatment was 
able to signiﬁcantly up-regulate the expression of Nrf2 and all the enzymes reported 
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in Fig. 7.7. In particular, in the co-treated cells the expression of GSTp2, HO-1, GR, 
NQO1 and TrxR1 was higher with respect to SF-treated cardiomyocytes, suggesting 
that E2 boosts the upregulation of phase II enzymes induced by SF. On the other side, 
E2 did not influence the expression of any considered gene. Regarding SOD1, SOD3 
and GPX, their mRNA levels were not inﬂuenced by any treatments (Fig. 7.8). 
 
 
 
Figure 7.7. Effect of  E2 and SF on the mRNA level of GSTM1, GSTp2, GSTa3, HO-1, GR, CAT, NQO1, 
TrxR1, Nrf2 in cardiomyocytes. Cells were treated with 0.5 μM SF in absence/presence of 10 nM E2 for 24 
h. Total RNA was isolated and the mRNA level of target genes was quantified using RT-PCR normalized to 
β-actin and β2-microglobulin housekeeping genes as reported in Materials and Methods. Triplicate 
reactions were performed for each experiment. Each bar represents the mean ± SEM of 3 independent 
experiments. Data were analyzed by one-way analysis of variance (ANOVA) followed by Bonferroni’s test. * 
p < 0.05 with respect to control; § p < 0.05 with respect to SF. 
 
 
 
HO-1 
TrxR1 
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Figure 7.8. Effect of  E2 and SF on the mRNA level of GPX, SOD1 and SOD3 in cardiomyocytes. Cells 
were treated with 0.5 μM SF in absence/presence of 10 nM E2 for 24 h. Total RNA was isolated and the 
mRNA level of target genes was quantified using RT-PCR normalized to β-actin and β2-microglobulin 
housekeeping genes as reported in Materials and Methods. Triplicate reactions were performed for each 
experiment. Each bar represents the mean ± SEM of 3 independent experiments. Data were analyzed by one-
way analysis of variance (ANOVA) followed by Bonferroni’s test. 
 
 
To further study the modulation of Nrf2 by SF/E2 co-treatment, we measured it by 
immunoﬂuorescence staining (Fig. 7.9) and by Western blotting analysis (Fig. 7.10). 
As reported in Materials and Methods, for immunofluorescence analysis, cells were 
seeded in coverslips, and at the end of each treatment, cells were fixed and incubated 
with an anti-Nrf2 specific antibody. As for the RT-PCR data, E2 did not increase 
total level of Nrf2 protein expression (Fig. 7.9); meanwhile, SF and the co-treatment 
induced a positive staining for Nrf2 with respect to control cells. Of note, the co-
treatment increased Nrf2 protein expression more effectively than SF alone. In order 
to investigate the translocation of Nrf2 to the nucleus, we treated cells with SF or E2 
and then performed immunoblot analysis of the cytosolic and nuclear fractions (Fig. 
7.10) using a specific Nrf2 antibody. Data revealed that E2 treatment reduced Nrf2 
protein level in the cytosolic fraction without increasing Nrf2 level in the nuclear 
fraction. On the contrary, both SF and the co-treatment were able to signiﬁcantly 
reduce Nrf2 expression in the cytosolic fraction and, at the same time, to signiﬁcantly 
increase Nrf2 in the nucleus. In particular, the Nrf2 translocation to the nucleus was 
higher in co-treated cells. 
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Figure 7.9. Effect of E2 and SF on Nrf2 protein expression in cardiomyocytes. Cells were treated with 0.5 
µM SF in absence/presence of 10 nM E2 for 24 h. Nrf2 was detected using an immunofluorescence staining 
with anti-Nrf2 antibody as reported in Material and Methods. Images were acquired with a 100x objective. 
Nrf2: green fluorescence (FITC); Nuclei: blue fluorescence (DAPI). 
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Figure 7.10. Effect of E2 and SF on Nrf2 translocation. Cells were treated with 0.5 μM SF in 
absence/presence of 10 nM E2 for 24 h, and cytosolic and nuclear extracts were immunoblotted with anti-
Nrf2 antibody as reported in Materials and Methods. Relative amounts were normalized to the intensity of β-
actin (cytosolic fraction) or lamin A (nuclear fraction) and represented as fold increase with respect to 
control. Data were analyzed by one-way ANOVA followed by Dunnett's test. *p<0.05 with respect to control 
cells; §p<0.05 with respect to SF. 
 
 
7.3. Involvement of ERα and ERβ in SF/E2 co-treatment counteracting H2O2-induced 
damage 
 
E2 mediates its physiological functions through the activation of estrogen receptors. 
So, we next analyzed the expression of both ERα and ERβ by RT-PCR in neonatal 
cardiomyocytes treated with 0.5 μM SF in the absence/presence of 10 nM E2 (Fig. 
7.11). Both receptors are expressed in the cells, and the treatments did not alter their 
mRNA levels. To investigate whether ERα or ERβ could influence E2 ability to boost 
SF protection against H2O2, we examined cell viability of cells co-treated with SF and 
E2 in the absence/presence of speciﬁc ERα and ERβ antagonists, MPP and PHTPP, 
respectively, before oxidative stress induction (Fig. 7.12). Both antagonists, MPP and 
PHTPP did not modify cell viability with respect to control cells. Interestingly, 
neither MPP nor PHTPP, reduce the efficacy of SF/E2 co-treatment against H2O2-
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induced damage, suggesting that ERs are not involved in co-treatment-mediated 
cardioprotection.  
 
 
 
 
Figure 7.11. Effect of  E2 and SF on the expression of ERα and ERβ in cardiomyocytes. Cells were 
treated with 0.5 μM SF in absence/presence of 10 nM E2 for 24 h. Total RNA was isolated and the mRNA 
level of target genes was quantified using RT-PCR normalized to β-actin and β2-microglobulin housekeeping 
genes as reported in Materials and Methods. Triplicate reactions were performed for each experiment. Each 
bar represents the mean ± SEM of 3 independent experiments. Data were analyzed by one-way analysis of 
variance (ANOVA) followed by Bonferroni’s test. 
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Figure 7.12. Effect of ERα and ERβ antagonists on H2O2-induced damage in cardiomyocytes. Cells were 
co-treated with 0.5 µM SF and 10 nM E2 in the absence/presence of 100 nM MPP (ERα antagonist) or 100 
nM PHTPP (ERβ antagonist) for 24 h prior to H2O2 exposure. Cell viability was measured by MTT assay as 
reported in Materials and Methods. Each bar represents means ± SEM of  at least 4 independent 
experiments. Data were analysed by one-way ANOVA followed by Bonferroni’s test. *p <0.05 with respect 
to control; °p< 0.05 with respect to H2O2; 
 
 
7.4 Effect of E2 and SF on ERK1/2 and Akt signaling 
 
We next evaluated the effect of E2 and SF on two pro-survival signaling pathways in 
cardiomyocytes 
303, 304
, ERK1/2 and Akt pathways by Western Blot analysis (Fig. 
7.13). Cells were treated with 0.5 μM SF in the absence/presence of 10 nM E2 for 
different time points (30 min, 2 h and 6 h) and then the phosphorylated- and total-
forms of ERK1/2 and Akt kinases were analyzed by immunoblotting, using specific 
antibodies. ERK1/2 was rapidly activated (phosphorylated) by all treatments, but 
only SF/E2 co-treatment maintained ERK1/2 activation at 2 and 6 h, suggesting a 
synergic effect of SF and E2 on the phosphorylation of this MAPK. 
Like ERK1/2, Akt was rapidly phosphorylated by SF, E2 and the co-treatment but at 
2 h, only E2 and the co-treatment were able to maintain Akt activation. Noteworthy, 
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with the exception of 6 h time point, SF/E2 co-treatment induced a significantly 
greater Akt activation than the single treatments.  
 
 
 
 
 
 
Figure 7.13. Modulation of ERK1/2 and Akt by SF/E2 co-treatment in cardiomyocytes. Cells were pre-
treated with 0.5 μM SF in the absence/presence of 10 nM E2 for different times (30 min–6 h), and proteins 
were separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis, immunoblotted and probed 
for total and phosphorylated forms of ERK1/2 and Akt as reported in Materials and Methods. Each bar 
represents means ± SEM of at least three independent experiments. Data were analyzed by one-way ANOVA 
followed by Bonferroni's test. *p<0.05 with respect to C; §p<0.05 with respect to SF, E2. 
 
 
To characterize the role of these two kinases on the enhanced cardioprotection 
elicited by SF/E2 co-treatment against oxidative injury, we verified the viability of 
 
 
 
 
 
A 
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cells pre-treated with SF/E2 co-treatment in the absence/presence of speciﬁc ERK1/2 
and Akt inhibitors, PD and LY, respectively, before the induction of oxidative stress 
(Fig. 7.14). Interestingly, only when the cells were simultaneously exposed to the two 
inhibitors, a signiﬁcant reduction of cell viability was recorded with respect to SF/E2-
treated cells. 
 
 
 
Figure 7.14. Effect of Akt and ERK1/2 inhibitors on H2O2-induced damage in cardiomyocytes.. Cells were 
treated with SF/E2 co-treatment in the absence/presence of 10 μM LY or 10μM PD prior to H2O2 exposure. 
Cell viability was measured by MTT assay as reported in Materials and Methods. Each bar represents 
means ± SEM of at least three independent experiments. Data were analyzed by one-way ANOVA followed 
by Bonferroni's test. °p<0.05 with respect to H2O2, §p<0.05 with respect to SF/E2 + H2O2 cells. 
 
 
7.5 Involvement of ERs and GPR30 in the activation of Akt kinase in H9c2 cells 
 
Our next aim was to better characterized the effect of SF/E2 co-treatment on Akt 
signaling pathway. To this purpose, we used the cardiomyoblast cell line H9c2. To 
verify that the co-treatment of H9c2 cells elicits the same effect observed in 
cardiomyocytes on Akt activation, we treated H9c2 cells with 0.5 μM SF in the 
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absence/presence of 10 nM E2 for different time points (30 min, 2 h) and then the 
phosphorylated- and total-forms of Akt kinase were analyzed by immunoblotting. 
Akt was rapidly activated by all treatments at 30 min, with SF/E2 co-treatment most 
effective that the other treatments (Fig. 7.15). To analyze the possible involvement of 
estrogen receptors in the activation of Akt induced by SF/E2 co-treatment, we treated 
H9c2 cells with selective agonists of ERα, ERβ and GPR30 and analyzed the 
activation of Akt by western blotting. 
 
 
 
 
 
Figure 7.15. Modulation of Akt by SF/E2 co-treatment in H9c2 cells. Cells were treated with 0.5 μM SF in 
the absence/presence of 10 nM E2 for different times (30 min–2 h), and proteins were separated by sodium 
dodecyl sulfate polyacrylamide gel electrophoresis, immunoblotted and probed for total and phosphorylated 
forms of Akt (A)  as reported in Materials and Methods. We used as positive control (PC) cells starved for 1h 
in DMEM w/o FBS and then exposed to 10% FBS DMEM for 20 min. C1: DMEM 30 min; C2: DMSO 30 
min (as SF+E2 treatment); C3: DMSO 2h (as SF+E2 treatment). Each bar represents means ± SEM of at 
least three independent experiments. Data were analyzed by one-way ANOVA followed by Bonferroni's test. 
*p<0.05 with respect to C2, §p<0.05 with respect to SF and E2. 
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As illustrated in Fig. 7.16 (A), we used PPT, agonist for ERα, at two different 
concentrations (10 nM and 100 nM) in absence/presence of 0.5 µM SF. SF and 10 
nM PPT alone were able to induce the activation (phosphorylation) of Akt; whereas 
SF/PPT co-treatments did not activate Akt kinase at any agonist concentration tested. 
Indeed, rather than enhancing SF-induced Akt activation, PPT inhibited its activation. 
To test ERβ contribution to Akt activation, we treated cells with 0.5 µM SF in 
absence/presence of KB5, agonist of ERβ, at two different concentrations (10 nM and 
100 nM) (Fig. 7.16 B). SF and 10 nM KB5 alone significantly activated Akt, 
meanwhile the SF and KB5 co-treatments enhanced Akt activation, suggesting that 
KB5 agonist could act like E2 in enhancing Akt phosphorylation induced by SF. 
Finally, we verify GPR30 involvement using G1 agonist. Cells were treated with 0.5 
µM SF in absence/presence of G1 at two concentrations (100 nM and 1 µM) (Fig. 
7.16 C). SF alone induced Akt phosphorylation, meanwhile G1 alone did not act on 
Akt phosphorylation. However, in agreement with the data obtained with KB5 
agonist, SF treatment in the presence of 1 µM G1 significantly boosted Akt 
phosphorylation induced by SF. These results suggest that the contribution of E2 on 
SF/E2 co-treatment effect could be mediated by ERβ and GPR30. 
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Figure 7.16. Involvement of estrogen receptors in the activation of Akt kinase. Cells were treated with 0.5 
μM SF in the absence/presence of selective agonists for 30 min, and proteins were separated by sodium 
dodecyl sulfate polyacrylamide gel electrophoresis, immunoblotted and probed for total and phosphorylated 
forms of Akt as reported in Materials and Methods. (A) PPT is a selective agonist for ERα; (B) KB5 is a 
selective agonist for ERβ; (C) G1 is a selective agonist for GPR30. Each bar represents means ± SEM of at 
least three independent experiments. Data were analyzed by one-way ANOVA followed by Bonferroni's test. 
*p<0.05 with respect to C, §p<0.05 with respect to SF/agonist co-treatment. 
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7.6 Nrf2 activation and Akt signaling in H9c2 cells 
 
To further confirm the involvement of Nrf2/ARE pathway in the cardioprotection 
elicited by SF/E2 co-treatment, we evaluated Nrf2 ARE-binding activity through 
ELISA-based kit in H9c2 cells. Cells were treated with 0.5 μM SF in the 
absence/presence of 10 nM E2 and then Nrf2 ARE-binding activity was analyzed in 
nuclear extracts.  
In agreement with the data obtained in primary cardiomyocytes, the co-treatment 
demonstrated to be the most effective in increasing Nrf2 activity (Fig. 7.17).  
Akt kinase is involved in Nrf2 nuclear stabilization. Indeed, Akt activation results in 
inhibitory phosphorylation of glycogen synthase kinase-3 (GSK-3), which mediates 
Nrf2 export from the nucleus. Therefore, Akt-mediated GSK-3 inhibition prevents 
Nrf2 proteosomal degradation 
305
. For this reason, we used a specific Akt inhibitor to 
study the involvement of Akt activation by the co-treatment in Nrf2/ARE pathway. 
To confirm LY ability to inhibit Akt activation we co-treated cells with SF and E2 in 
the absence/presence of LY before performing western blot analysis (Fig. 7.18). As 
expected, in presence of LY co-treatment-induced Akt phosphorylation was 
significantly reduced. So we next verified the effect of the co-treatment in 
absence/presence of LY on Nrf2 ARE-binding activity by ELISA-based kit (Fig. 
7.19). As illustrated in Fig 7.18, SF and E2 co-treatment significantly increased Nrf2 
activity, meanwhile, in the presence of LY, the activation of Nrf2 induced by the co-
treatment was prevented. These results suggest a key role played by Akt kinase in co-
treatment-induced Nrf2 activation.  
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Figure 7.17. Effect of E2 and SF on Nrf2 binding activity. Cells were treated with 0,5 μM SF in 
absence/presence of 10 nM of E2 for 6h. ARE binding activity of Nrf2 was analyzed in nuclear extracts using 
the ELISA-based kit Trans AM Nrf2 as reported in Materials and Methods. Values represent means ± SEM 
of 3 independent determinations and are reported as fold increase over controls. Data were analyzed by one-
way ANOVA followed by Bonferroni’s test. *p< 0.05 with respect to C. 
 
 
 
 
 
Figure 7.18. Effect of SF/E2 co-treatment on Akt phosphorylation in presence of Akt inhibitor. Cell were 
treated with SF/E2 co-treatment for 30 min in absence/presence of 10 µM LY inhibitor. Proteins were 
separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis, immunoblotted and probed for total 
and phosphorylated forms of Akt as reported in Materials and Methods. *p<0.05 with respect to C; §p<0.05 
with respect to SF/E2 co-treatment. 
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Figure 7.19. Effect of co-treatment on Nrf2 binding activity in presence of Akt inhibitor. Cells were treated 
with the co-treatment for 6 h in absence/presence of  10 μM LY. ARE binding activity of Nrf2 was analyzed 
in nuclear extracts using the ELISA-based kit Trans AM Nrf2 as reported in Materials and Methods. Values 
represent means ± SD of 3 independent determinations and are reported as fold increase over controls. Data 
were analyzed by one-way ANOVA followed by Bonferroni’s test. *p < 0.05 with 
respect to C; §p < 0.05 with respect to SF/E2 co-treatment. 
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8. DISCUSSION 
 
 
In 2010, the prestigious journal Nature, entitled its editorial as 'Putting gender on the 
agenda', underling that still nowadays, the medications used on women have been 
prevalently tested on men 
306
. Indeed, from Ippocrates to the modern medicine, 
preclinical and clinical studies including subjects of both sexes are really few. 
Women enrolled in clinical trials for cardiovascular disease medications represent 
only the 30%; and the first trial on statins (WOSCOP) did not enroll any woman, as 
well as that studying aspirin as preventive agent of CVD. The philosophy of drug 
development needed to change from the paradigm of 'one size fits all' to a new 
concept of precision medicine. Women and men can be affected by the same 
pathologies but they show differences in the age of onset, symptoms, risk factors, 
pathology progression and not less important, they respond differently to the 
medications. These discrepancies are due to those we refer to as sex-gender 
differences. Women and men are biologically different at the level of the cells, the 
organs and the organism 
307
. Sex leads to biological differences between males and 
females, in terms of endocrinology, epigenetics and genetics, while gender refers to 
individual interaction with the society and environment. Gender concept is specific 
for humans, while sex differences can be evidenced in animal models and isolated 
cells. The impact of sex-gender differences is well studied in the field of 
cardiovascular disease. Nowadays, CVD are still the first cause of death worldwide, 
and despite the improvement of their prevention, in the elderly CVD represent the 
first cause of disability 
1
. CVD rarely manifest in pre-menopausal women meanwhile, 
the incidence of these pathologies dramatically increases after the menopause. This 
phenomenon has been in part correlated to the lost of sexual hormones after 
menopause, in particular to the lower levels of 17β-estradiol, the main premenopausal 
circulating form of estrogen 
4
. In post-menopausal women, oxidative stress status 
could represent a helpful biomarker for the risk of cardiovascular disease. Oxidative 
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stress is a condition of disequilibrium between oxidative species, mainly reactive 
oxygen species, and the endogenous antioxidant defenses, and it leads to high level of 
lipid peroxidation, oxidative damage to DNA, mitochondrial dysfunction and altered 
protein expression. Oxidative stress represents the common characteristic in CVD, as 
it plays a role in the initiation and progression of these 
154, 308, 309
. In physiological 
conditions, cells are able to counteract the excess of intracellular ROS production 
through the endogenous antioxidant defense system, which belongs phase II and 
antioxidant enzymes. SOD, CAT, GST, GR, TrxR1, NQO1, HO-1 are examples of 
phase II enzymes, which play a key role in the maintenance of intracellular redox 
state and in the protection of cells from oxidative damages. In particular, Nrf2 
transcription factor represents the main regulator of these cytoprotective proteins. 
The intriguing possibility to counteract the elevation of ROS levels in CVD through 
dietetic intervention has been largely deepened, and many investigations reported 
cardioprotective effects played by nutraceutical compounds with several mechanisms, 
including the reduction of oxidative stress 
310, 311
. However, all studies investigating 
the cardioprotective role of nutraceutical compounds did not take into account sex-
gender differences.  
Sulforaphane is a dietary isothiocyanate, plant secondary metabolite, which derives 
from the hydrolysis of its precursor glucoraphanin, present in brassica vegetables. 
The main mechanism elicited by SF is the induction of a battery of cytoptotective 
enzymes through the involvement of Nrf2/ARE pathway 
229
. Several studies reported 
the cardioprotective role of sulforaphane in counteracting oxidative injury 
256, 285-287
. 
As mentioned before, it has been demonstrated that males and females respond 
differently to cardiovascular medications. These differences were mainly attributed to 
the actions of E2, so we hypothesize that sex hormones could also differently 
influence the preventive/protective effects of nutraceutical compounds in males and 
females, such as those of SF. 
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Aim of this PhD thesis was to explore the modulatory effect of E2 on the 
cardioprotective activity of SF in primary cultures of rat cardiomyocytes against 
oxidative stress by analyzing antioxidant/survival pathways and investigating 
the involvement of ERs and GPR30. 
 
In this thesis we focused on the effects of E2 on SF protection against oxidative 
damage in primary cardiomyocytes. And to the best of our knowledge, for the first 
time we demonstrated that estrogen could modulate the protective activity of a 
nutraceutical compound. In particular, our data show that E2 can enhance SF capacity 
to counteract oxidative injury by boosting the up-regulation of antioxidant enzymes 
and the activation of pro-survival signaling pathways. Our data evidence that E2 
significantly enhances SF cardioprotection against oxidative injury. Previous studies 
demonstrated that 5 µM SF is able to protect against oxidative damage, inducing a 
panel of key cellular cytoprotective enzymes 
253, 256, 302
. Interestingly, in these 
previous studies, only 5 µM SF led to a total protection of cardiomyocytes against 
oxidative stress. In this thesis, we used 0.5 µM SF, a 10-fold lower concentration 
which, in absence of E2, led to a slight protection in cardiomyocytes; meanwhile, in 
presence of E2, it induced a full protection against oxidative injury. Differently, E2 
alone did not protect from H2O2-induced oxidative injury. Data from Urata et al. 
312
 
are in accordance with our data, as they showed that 10 nM E2 was not able to 
contrast oxidative injury elicited by H2O2; differently, other researchers observed 
protective effects with E2 treatment against different damages, in cardiomyoblast cell 
line. In H9c2 cells, Hsieh et al. 
33
 demonstrated that 10 nM E2 is able to reduce 
hypoxia-induced apoptosis. Likewise, Kim et al 
27
, and Cong et al. 
32
, using the same 
E2 concentration on neonatal cardiomyocytes, showed protective effects against H/R-
induced apoptosis. The dissimilarity between our data and these results could be 
attributed to the different injury induced to cells, as H/R leads to a more complex 
scenario than H2O2, involving other mechanisms beside oxidative stress. To further 
confirm the observation that E2 boosts SF protective effect against oxidative damage, 
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we evaluated the effect of E2 on SF protection in another oxidative stress model. 
Therefore, we exposed cardiomyocytes to the alpha-oxoaldehyde MG, which widely 
demonstrated to induce oxidative stress 
300, 301
. According to the data obtained with 
H2O2, E2 demonstrated to enhance SF protection against MG, suggesting that E2 can 
modulate SF cardioprotection in different oxidative stress models. To deepen the 
mechanisms behind E2 ability to enhance SF protection against H2O2-induced 
damages, we also evaluated the effect of SF/E2 co-treatment on redox intracellular 
state, in cardiomyocytes exposed to peroxide. In agreement with the viability data, 
the SF/E2 co-treatment counteracted, more effectively than SF alone, intracellular 
ROS release and 8-OHdG formation induced by H2O2, suggesting a modulator effect 
of E2 on SF antioxidant capability. Differently, the recovery action on GSH levels of 
SF/E2 co-treatment, after peroxide exposure, was comparable to that of SF alone. 
In rat cardiomyocytes, 5 µM SF demonstrated to up-regulate several antioxidant and 
phase II enzymes, so counteracting oxidative stress 
253, 256, 302
 through the involvement 
of Nrf2 transcription factor. Genes codifying for phase II enzymes contain in their 
promoter regions ARE (antioxidant responsive element) sequence, which is 
recognized from Nrf2 
180
. These enzymes represent key components of the cellular 
antioxidant defense system and are important for the prevention/protection of the 
CVD 
313
. The importance of Nrf2/ARE signaling pathway has been widely explored 
in the cardio-prevention of oxidative injury 
293, 314
, as well as in the protection from 
heart dysfunction 
315-317
. In this project, SF capacity to induce antioxidant enzymes 
was significantly enhanced by E2; in particular, SF/E2 co-treatment significantly up-
regulated the expression of NQO1, TrxR1, GR, GSTp2, HO-1 and Nrf2 with respect 
to SF alone. Interestingly, E2 alone did not influence the expression level of any 
tested enzyme. To verify the mechanism behind the induction of phase II enzyme and 
Nrf2 mRNA levels elicited by SF/E2 co-treatment, we studied the effect of SF and E2 
on Nrf2 nuclear translocation. Indeed, Nrf2 is known to induce, once translocated 
into the nucleus, itself expression beyond that of antioxidant enzymes 
248
. The co-
treatment significantly enhanced Nrf2 nuclear accumulation with respect to SF alone, 
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so suggesting that E2 is able to boost the up-regulation of phase II enzymes induced 
by SF through Nrf2. Interestingly, E2 alone led to a reduction in Nrf2 cytosolic level, 
which did not correspond to an increase in Nrf2 nuclear level. As E2 did not show to 
modulate neither antioxidant enzymes expression nor Nrf2 expression with respect to 
control cells, the reduction in Nrf2 cytosolic level might involve different 
mechanisms. Recently, novel E3 ubiquitin ligases has been identified that mediate 
Nrf2 degradation via Keap1-indipendent mechanisms 
318
. We can hypothesize that E2 
mediates the release of Nrf2 from Keap1 but the free Nrf2 is rapidly degraded before 
its translocation to the nucleus with a Keap1-indipendent mechanism. Obviously, 
further investigations are needed to verify this hypothesis. 
Our data on E2 effect on Nrf2 activation are not in agreement with the results 
obtained by Yu et al. 
319
, as they showed the activation of Nrf2 and the induction of 
HO-1, SOD1 and GST with 5 µM E2. In our opinion, these discrepancies between 
our and their results are not surprising, as we used physiological concentration of E2 
(10nM), that is one order of magnitude lower than the ones used by Yu et al. 
E2 mediates its physiological functions through genomic and non-genomic pathways 
320. The firsts can be mediated by ERα and ERβ, which in the classical mechanism act 
as transcription factors; whereas non genomic signaling is modulated by membrane-
associated ERα and ERβ 321, and by the G protein–coupled receptor named as 
GPR30, which is the main responsible for estrogen effects acting via non-classic 
receptor systems 
116
. All receptors are expressed in cardiac cells 
46, 322
 from both male 
and female rodents 
112, 323, 324
. Different authors suggested that E2 cardioprotection 
against oxidative stress is mediated by ERs. In H9c2 cardiomyoblasts, E2 exerted 
protection from H2O2-mediated injury through a transcriptional modulation 
mechanism controlled by ERβ 312. In another study, E2 treatment counteracted, in rat 
cardiomyocytes, H/R-induced damage with a mechanism mediated by ERα via the 
up-regulation of corticotrophin-releasing hormone receptor type 2 
32
. 
In our study, we used specific ERα and ERβ antagonists (MPP and PHTPP, 
respectively) but we did not observe a reduction in the protective effect elicited by 
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SF/E2 co-treatment, suggesting that probably E2 enhances SF cardioprotection 
against oxidative injury without the involvement of ERs. 
A battery of protein kinases, including Akt and ERK1/2, showed to exert 
cardioprotective activity against oxidative stress 
325
; so we hypothesized that in the 
enhanced protection elicited by SF/E2 co-treatment, Akt and ERK1/2 signaling 
pathways could be involved. 
Several studies showed a beneficial role of ERK1/2 pathway in the heart 
326
. Once 
activated, ERK1/2 can phosphorylate many intracellular targets at both cytoplasmic 
and nuclear level. ERK1/2 cytosolic targets include approximately 70 proteins 
327
, 
while in the nucleus it phosphorylates multiple transcription factors, inducing gene 
expression in the heart 
328
. Interestingly, ERK1/2 activation was markedly higher in 
SF/E2 co-treated cells with respect to single treatments, suggesting a synergic effect 
of SF and E2 on the phosphorylation of this MAPK. 
Akt is a serine/threonine kinase which modulates several aspects of cellular 
functions, such as growth, survival and metabolism, and its upstream kinase is PI3K 
329, 330
. After 30 min, all treatments increase Akt phosphorylation with respect to 
control cells; meanwhile at 2h, only E2 and the co-treatment maintained Akt 
activation; nevertheless, the co-treatment greatly activated Akt with respect to SF or 
E2 alone, so suggesting a potential contribution of E2 in the regulation of this 
protective kinase. Our data are in agreement with previous observations on E2 
capacity to activate Akt signaling pathway in cardiac cells 
26, 312
. Moreover, these 
effects cannot be explained by a simple additive effect of E2 and SF but rather by a 
synergic action.  
To better clarify the role of these two kinases on enhanced cardioprotection of SF 
induced by E2, we used specific inhibitors of Akt and ERK1/2 phosphorylation (LY 
and PD, respectively). Of note, only the simultaneously presence of both inhibitors, 
significantly reduced co-treatment protective effect against oxidative injury. This is 
not surprising, because these kinases often have the same target protein, and can act 
in concert to promote cell survival 
331
. Examples are forkhead box O (FOXO) and c-
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Myc transcription factors BCL2-associated agonist of cell death and GSK3 
332-335
. To 
better characterize the contribution of E2 on Akt phosphorylation, we used receptor 
selective agonists. In particular, we selected PPT, KB5 and G1 as selective agonists 
for ERα, ERβ and GPR30, respectively. The co-treatment with SF and PPT did not 
activate Akt kinase, so implying no involvement of ERα in SF/E2 co-treatment 
synergic effect on Akt phosphorylation. Meanwhile, co-treatment with SF and KB5 
or G1 agonists enhanced the activation of Akt with respect to single treatments, 
suggesting a role for these two receptors in the modulation of Akt phosphorylation. 
Moreover, it has been widely demonstrated the involvement of Akt signaling 
pathway in the nuclear accumulation and activation of Nrf2 
179, 253
. As expected, the 
inhibition of Akt phosphorylation by LY led to a reduction of the ARE-binding 
activity of Nrf2 induced by SF/E2 co-treatment, suggesting, once more, a role for this 
kinase in the protective effects elicited by SF/E2 co-treatment. 
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9. CONCLUSION 
 
 
Our data show that E2 enhances SF protective effects against oxidative damage in 
cardiomyocytes. In particular, E2 enhanced the expression of antioxidant enzymes 
induced by SF through the involvement of Nrf2/ARE pathway, and the activation of 
cardioprotective signaling pathways. Interestingly, our findings reveal that the 
enhanced protective effects elicited by SF in presence of E2 can only be related to a 
synergic effect between the bioactive compound and the hormone. Therefore, this 
study suggests that nutraceutical efficacy might be modulated by sex hormones. 
Moreover, it provides promising indications for the promotion of a isothiocyanate-
rich diet for cardiovascular prevention in women.  
In conclusion, the data open new avenues for further researches and strengthen the 
concept that, similarly to studies on drugs, investigations on bioactive compounds 
should take into account sex-gender differences. 
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